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Gregory M. Cooper, PhD 
University of Pittsburgh, 2006
 
In cases of craniosynostosis, defined as the premature fusion of the cranial sutures, there is a 
need to inhibit bone formation in small calvarial defects to avoid the occurrence of postoperative 
resynostosis. Similarly, reconstruction of bone in the craniofacial skeleton following injury or 
tumor resection necessitates controlled bone regeneration to avoid bone overgrowth. Bone 
morphogenetic proteins (BMPs) are potent bone inducing growth factors that are expressed 
during normal bone healing. Noggin is an extracellular antagonist to BMPs. This work studied 
the use of Noggin to prevent postoperative resynostosis in a rabbit model of human 
nonsyndromic craniosynostosis via protein therapy. A mouse model of a healing suturectomy 
was also developed. This model was used to study the effects of Noggin ex vivo gene therapy on 
the inhibition of postoperative resynostosis. Finally, the ability of Noggin to inhibit bone 
overgrowth and improve BMP4-induced bone formation was tested. The work presented here 
demonstrates that a single dose of Noggin protein is capable of inhibiting resynostosis and 
improving craniofacial growth after surgery to correct craniosynostosis in rabbits. Noggin 
delivered through ex vivo gene therapy was able to inhibit bone formation in a novel mouse 
model. Also, the implantation of Noggin expressing cells along with BMP4 expressing cells 
reduced ectopic bone formation and improved bone density. These results suggest that Noggin 
therapy may be useful for the inhibition of postoperative resynostosis in children with 
craniosynostosis. Furthermore, by recreating naturally occurring expression patterns (for 
example, both Noggin and BMP4), we may be able to control the size, shape and quality of bone 
formed by biologically-driven therapies. 
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1.0 INTRODUCTION 
1.1 CLINICAL STUDIES OF CRANIOSYNOSTOSIS 
1.1.1 Occurrence of Craniosynostosis 
Craniosynostosis (CS) is a pathological condition defined as the premature fusion of the sutures 
of the skull—i.e., fusion happens before cessation of brain growth which, in 90% of humans, 
occurs by 6 years of age [1]. CS has been reported in Asian-, African-, and European-derived 
populations [2], and the birth prevalence of the condition is estimated to be 300–500 cases per 
1,000,000 live births [2]. CS involves the overgrowth of bone at the osteogenic fronts of the 
developing cranial bones. Normally, where osteogenic fronts meet each other, a region of tissue 
between the fronts remains undifferentiated. This region of non-bony tissue (the suture) allows 
for prenatal and postnatal brain growth. In CS, bone growth is accelerated (hyperostotic) at the 
osteogenic fronts, and the region between the fronts differentiates into bone and obliterates the 
suture, leading to a bone-filled joint between osteogenic fronts (synostosis). Sagittal suture 
synostosis is the most common type (approximately 55% of total cases), followed by coronal 
suture synostosis (approximately 24%), multiple suture synostosis (approximately 10%), metopic 
suture synostosis (approximately 7%), and lambdoidal suture synostosis (approximately 4%) [2]. 
Approximately 72% of sagittal cases are sporadic, with a male preponderance of 3.5:1. No 
paternal or maternal age effects have been reported. The 6% of cases that are familial usually are 
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inherited as an autosomal dominant condition with 38% penetrance. Sporadic coronal cases 
account for approximately 61% of all cases, with a female preponderance of 2:1 and an advanced 
paternal age effect. More coronal synostosis cases than sagittal synostosis cases are familial. Ten 
to 14% of nonsyndromic coronal cases are inherited as an autosomal dominant condition with 
60% penetrance. Most autosomal dominant CS syndromes involve the coronal suture. When CS 
is a symptom of a syndrome, it usually is associated with facial, limb, ear, or heart malformations 
(Figure 1) [2, 3]. 
 
 
Figure 1: Photographs of Patients with Craniosynostosis. 
A) Crouzon Syndrome. B) Apert Syndrome. C) Pfeiffer Syndrome. D) Jackson-Weiss Syndrome. Notice that the 
child with Apert Syndrome (B) has a fusion of the coronal suture, causing the skull to grow shorter, but also taller 
and wider. From Jabs et al., 2002 [3]. 
 
1.1.2 Management of Craniosynostosis 
Premature suture fusion leads to secondary deformities in the cranial vault, cranial base, and 
midface [4-14]. Such skeletal deformities often result in significantly elevated intracranial 
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pressure [15-22], altered intracranial volume [20, 23-25], and dilation of the subarachnoid spaces 
[26], events that may result in optic nerve compression, papilledema, and, if left uncorrected, 
optic atrophy, blindness [27], cognitive disabilities, and mental retardation [16, 20, 27-30]. Such 
severe craniofacial growth, ocular, and neural abnormalities pose extensive, costly, and (often) 
recurrent clinical and surgical management problems [4, 28, 31-37]. 
The goals of current therapy for and surgical management of CS include the following: 1) 
to provide adequate intracranial volume for normal brain growth and development, 2) to re-
establish normal intracranial fluid pressure dynamics, and 3) to correct the progressive cosmetic 
skeletal deformity [2-4, 28, 31-44]. The timing and sequence of these procedures vary according 
to the number of affected sutures, the severity of the secondary deformities, and the functional 
and psychological needs of the patient. Surgical management typically comprises the following 
actions: 1) surgical release of the synostosed suture, cranial vault decompression, and upper 
orbital reshaping and advancement (during infancy at approximately 3–12 months of age); 2) 
surgical correction of midfacial deformities (during childhood at approximately 4–12 years of 
age); and 3) orthognathic surgery to correct jaw discrepancies (during adolescence at 
approximately 14–18 years of age) [2-4, 28, 31-33, 38, 41-44]. 
1.1.3 Postoperative Resynostosis 
Although these techniques have enabled clinicians to achieve the goals stated above, the 
suturectomy site frequently reossifies very rapidly (in 30%–100% of reported cases and, in some 
cases, as early as 6 months after surgery) [28, 38, 44-52], particularly in cases involving the use 
of simple suturectomies or linear craniectomies [38, 52]. Pancraniosynostosis (fusion of all of the 
cranial sutures) has even been reported after surgical correction of single suture synostosis [53]. 
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This rapid resynostosis can increase intracranial pressure, further restrict the growing brain and 
cranial base, and alter craniofacial growth [4, 5, 54]. To overcome such reossification problems, 
researchers and clinicians have devised and used a number of clinical strategies [28, 34, 35, 37, 
55]. Initial attempts at preventing previously released stenosed sutures from reclosing involved 
wrapping the intact bony margins with a barrier. However, new bone rapidly overgrew the 
barrier and reossified the suturectomy site, necessitating the performance of additional invasive 
surgeries [56]. New suture formation was never observed by clinicians using this method. 
Alternatively, other clinical investigators have used techniques designed to chemically damage 
the dura and reduce its osteogenic potential [55, 57, 58]. The frequency of resynostosis decreased 
with the use of these techniques, but seizures and neurological problems typically resulted, 
probably due to the toxic effects of the chemical adjuvants used in the technique [28, 55]. Yet 
another approach involves extensive surgical intervention and radical repositioning of the 
calvarial bones, performed in part to keep the margins of the craniectomy sites from physically 
reapproximating and resynostosing [4, 28, 31-33, 35, 38, 41-44, 55, 59]. Although sutural 
reossification is less of a problem with the aforementioned techniques, the rates for other 
complications resulting from these high-risk procedures range from approximately 15%–25% 
and include osseous relapse and instability, severe intraoperative blood loss, convulsions, 
infections, conjunctival chemosis/facial swelling, and soft tissue necrosis [28, 32, 44, 49, 51, 55, 
60, 61]. Major complications can require additional surgical procedures to correct (with 
reoperation rates ranging from 6%–27%) [60, 61], which in turn increase patient morbidity and 
mortality. 
 These findings suggest that much more research is necessary to improve the clinical and 
surgical management and the eventual quality of life for infants born with craniosynostotic 
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defects. The importance of developing biologically-based therapies that could be combined with 
earlier and less radical surgical interventions is evident. This approach must prevent postsurgical 
resynostosis, re-establish the normal intracranial fluid pressure dynamics, improve craniofacial 
and neurocapsular growth, and obviate the need for multiple surgeries for neonates with various 
synostotic conditions. 
1.2 GROWTH FACTOR REGULATION OF BONE AND SUTURE 
MORPHOGENESIS 
At the present time, the literature contains only a few abstracts and full-length reports describing 
the phenotypic characteristics of osteoblasts from and protein expression profiles within 
craniosynostotic calvaria [62-71]. This paucity of information is related, in part, to the scarcity of 
homogeneic human tissue available for biochemical analysis (because tissue from 
craniosynostotic and normal control human neonates is difficult to obtain) and, until recently, the 
lack of a genetic animal model of CS.  
Although researchers have proposed numerous theories to account for premature suture 
closure in craniosynostotic patients, there is sufficient evidence to suggest that abnormal 
amounts of growth regulatory proteins are at least partially responsible for the osteogenic 
changes. In normal bone, certain proteins (e.g., transforming growth factor-beta1 [TGF-β1] and 
insulin-like growth factor 1 [IGF-1]) are known to enhance osteogenesis [69-77], whereas other 
proteins (e.g., interleukin-1 [IL-1] and tumor necrosis factor-alpha [TNF-α]) exert negative 
effects by directly inhibiting collagen and bone formation [72, 78, 79]. In addition, IL-1α, IL-1β , 
IL-6, and TNF-β all stimulate osteoclastic activity, but TGF-β1 inhibits it [72, 80]. In light of the 
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knowledge that growth factor induction is genetically controlled and that these osteogenic factors 
play a major role in bone development [72, 76, 81], it is reasonable to suggest that the enhanced 
osteogenesis noted in craniosynostotic individuals is at least partially attributable to alterations in 
growth factor production or regulation [38, 39, 63, 72, 81].  
1.2.1 Transforming Growth Factor Beta 
Several recent studies have demonstrated that normal suture maintenance and eventual fusion 
require soluble, heparin binding, growth factors secreted by the dura mater [62, 82-89]. The 
TGF-β isoforms constitute one such group of local growth factors that control osteogenic 
processes in cranial sutures [62, 65, 68, 72, 81-83, 86, 90, 91]. Three closely related TGF-β 
isoforms are present in mammals: TGF-β1, TGF-β2, and TGF-β3 [65, 72, 92-94]. TGF-βs are 
potent growth regulatory molecules that influence craniofacial development during early 
embryonic stages and subsequent stages of mesenchymal cell differentiation. The three isoforms 
are regulated by latency-associated proteins 1–3 (LAP1–3) and latent TGF-β binding proteins 1–
3 (LTBP1–3) [65, 95, 96]. When combined with LAP and LTBP, the growth factors are bound to 
the bone extracellular matrix (ECM) and are inactive. Plasmin cleaves LTBP from the ECM, and 
the LAP-TGF-β inactive complex binds to the cell membrane. At this point, TGF-β is released 
from LAP and becomes active [65, 95, 96]. The activated isoforms are particularly important in 
suture biology because they mediate the proliferation and differentiation of osteoblastic suture 
cells and effect fusion in vivo [62, 65, 72, 82, 83, 86, 90, 91].  
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 Figure 2: Diagram showing molecular interactions surrounding suture fusion. 
Modified from Opperman et al., 2002 [81]. 
 
 
Researchers have reported differential distribution gradients of TGF-β1, TGF-β2, and 
TGF-β3 in developing, patent, and fusing calvarial sutures and the dura mater in rodents and 
humans [62, 68, 82, 83, 97]. Such distribution gradients may be responsible for the regulation of 
normal suture morphology and for the various suture alteration zones observed histologically in 
sutures that fuse prematurely [81, 86, 90, 91, 98, 99]. Coordinated functional regulation of the 
TGF-β isoforms in these areas may be important because calvarial osteoblasts and sutures in 
craniosynostotic individuals exhibit accelerated bone formation rather than reduced bone 
resorption [18, 54, 64, 70, 71, 98-101]. Researchers also have demonstrated differential actions 
by these isoforms. TGF-β isoform–null mice show distinct craniofacial and somatic phenotypes 
depending on which isoform is knocked-out [102]. The inhibition of TGF-β2 by using 
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neutralizing antibodies will prevent suture obliteration, whereas the inactivation of TGF-β3 will 
induce fusion in sutures that normally remain patent [81, 91, 101, 103-105]. Thus the TGF-β 
isoforms appear to perform distinct biological functions, and differing distributions of these 
isoforms may play an important role in premature suture fusion. 
1.2.2 Fibroblast Growth Factors 
Several recent publications have associated certain mutations in FGF receptors with human 
developmental syndromes associated with prematurely fused sutures [3, 106, 107]. Because 
FGF-induced mitosis in osteoblasts precedes mineralization [108-110] and TGF-β1 
synergistically increases FGF-induced osteoblast mitogenicity [111], TGF-βs in the sutural 
region likely regulate the expression of FGFs or their receptors (Figure 2). Because mutations in 
FGF receptor 3 cause the most common form of dwarfism, achondroplasia [112], and a mutation 
in a TGF-β superfamily member causes a phenotypically similar defect in limbs and limb joints 
[113], a multifactorial system involving the FGFs and members of the TGF-β family may 
regulate suture development, function, and fusion. 
1.2.3 Transcription Factors 
The expression of FGFs, FGFRs, and TGF-βs also may be regulated by members of the Msx 
homeobox gene family [107, 114-119]. The human analogs of the Drosophila muscle-segment 
homeobox genes, Msx1 and Msx2 (previously HOX7 and HOX8), are expressed in an 
overlapping pattern during embryogenesis and organogenesis. Because their temporal and spatial 
patterns of expression are highly conserved in mammals and birds, they likely play a 
fundamental role in development. The human Msx2 gene is located in chromosome region 5q34-
 8 
q35. After Muller et al. mapped a gene for “Boston type” CS to this region [120], Jabs et al. 
[115] identified a mutation in the homeobox domain of Msx2 (missense: His→Pro7) in the same 
disorder. Msx2 overexpression also has been observed in the perisutural tissues of 25-day-old 
craniosynostotic rabbits when compared with age-matched wild-type rabbits (unpublished data 
from Dr. MP Mooney). Msx2 is expressed in differentiating cells at the margins of the skull 
bones. Under the control of local factors, these cells grow at the margins but do not normally 
fuse until completion of skull growth. 
Mutations in Msx2 may cause CS by allowing the premature differentiation of these 
Msx2-expressing cells [121] and the migration of cranial neural crest cells that form the calvarial 
bones, the mesenchyme of the sutural spaces, and the dura mater [114, 116, 122]. Recent 
experimental studies [116, 123] have induced CS by using a transgenic Msx2 mouse model. 
Researchers conducting these studies have suggested that Msx2 caused CS through a dominant 
gain-of-function effect, possibly by affecting TGF-β signals emitted from the dura mater, thus 
permitting the inappropriate growth of the calvarial bones that, in turn, resulted in premature 
sutural fusion [3, 116, 123]. CS also has been elicited by researchers using a transgenic FGF 
mouse model with a retroviral vector inserted 6 kb upstream of FGF4 between the tandem of 
FGF3 and FGF4 genes. Although the effect of the retrovirus on the expression of FGF4, FGF3, 
or both is not yet fully understood, this is the first craniosynostotic mutation found to involve a 
ligand in the FGF/FGFR transduction pathway [106]. FGFRs have been shown to coexpress with 
Msx2 at a variety of sites in the developing mouse embryo [114, 124, 125]. Also, TGF-βs have 
been shown to modulate Msx2 expression in the oral epithelium and the hindbrain [126, 127]. 
Consequently, it is possible that TGF-βs, FGFRs, and Msx2 might function together (possibly in 
the same epistatic pathway) to regulate the temporal sequence of suture development and help 
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coordinate the growth of the skull and that of the brain (Figure 2) [72, 107, 114, 116, 118, 128]. 
These findings suggest that, although research has elucidated a part of the normal chain of events 
leading to suture morphogenesis, the complex pathogenic mechanism(s) causing accelerated 
bone formation and CS remains poorly understood [39, 63].  
1.2.4 Noggin and Craniosynostosis 
Recently Warren et al. [129] have shown that the interaction between FGF receptor activity and 
CS is mediated by the BMP antagonist Noggin. These investigators used the mouse posterior 
frontal suture as a model for CS. The mouse posterior frontal suture generally undergoes fusion 
within the first 45 days of life, whereas all other sutures remain patent throughout the lifetime of 
the animal. After culturing cells obtained from the dura mater underlying the posterior frontal, 
coronal, and sagittal sutures, Warren et al. observed that the dural cells from underneath the 
posterior frontal suture, unlike those from underneath the coronal or sagittal sutures, exhibited 
reduced expression of Noggin concomitant with FGF-2 protein expression. The investigators 
were able to delay the fusion of the posterior frontal suture in vivo by using adenoviral 
transfection to increase Noggin expression. This dissertation attempts to investigate the ability of 
Noggin to inhibit bone formation in the craniofacial skeleton. 
In the developing embryo, Noggin protein is expressed in the Spemann organizer and was 
initially characterized by its ability to induce dorsal structures in Xenopus embryos [130]. 
Noggin is now known to antagonize the activity of BMP2, BMP4, and BMP7 by binding directly 
to the proteins and making them inactive [131, 132]. Because Noggin expression is reduced only 
in the dura mater underlying fusing sutures, researchers have postulated that BMP activity 
contributes to normal suture fusion. Because Noggin acts by binding to and inactivating BMPs, 
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Noggin’s effect on delaying suture synostosis suggests that the BMP signal may be involved in 
cranial suture fusion. Rice et al. [133] have demonstrated that the addition of BMP2-soaked 
agarose beads to the calvarial suture mesenchyme in mice up-regulates the expression of Msx2 in 
the tissues surrounding the beads. As discussed above, gain-of-function mutations in Msx2 lead 
to CS [106, 107, 116]. The data from these studies enable us to propose a pattern of protein 
expression and interaction that may be involved in the fusion of calvarial sutures (Figure 3). 
 
 
Figure 3: Proposed pathway of protein expression and interaction during suture fusion. 
 
   
Recent advances in our understanding of the molecular events that occur during normal suture 
fusion and craniosynostosis [30, 81], when combined with novel techniques developed to 
engineer craniofacial tissues [134-136], may enable us to design therapeutic strategies to enhance 
the current surgical treatment of craniosynostosis, thereby decreasing the complications inherent 
in current surgical procedures [38, 54, 81, 83, 101, 106, 129, 137]. A minimally invasive surgery, 
when assisted by a molecular therapy, may allow for normal brain growth patterns, restore 
normal intracranial volume and intracranial pressure, and alleviate the need for extensive 
craniofacial reconstruction. 
1.3 PROGRESS TOWARD THE IMPROVEMENT OF BONE HEALING 
Less than optimal healing after bone damage is a common problem encountered by 
reconstructive surgeons. Although most bone defects heal well, difficulties such as delayed union 
or non-union can be devastating. To treat non-unions, clinicians often use autologous bone-
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grafting techniques. A recent review reports that approximately 1.5 million bone-grafting 
operations are performed each year in the United States [138]. Autografting, which uses bone 
grafts taken from other bones within a patient, is the current gold standard for care. 
Unfortunately, donor site morbidity [139], the lack of available harvest sites (especially in the 
pediatric population), and the high risk of suboptimal outcomes have all lowered the appeal of 
autografts [140]. Consequently, there is intense interest in improving fracture treatment through 
the use of allografts, defined as bone substitutes obtained from sources other than the patient. 
Synthetic materials currently used for bone reconstruction include metal prostheses, 
calcium phosphate-based ceramics and pastes, methyl methacrylate constructs, and polymers 
[141-144]. These materials are useful to varying degrees; their overwhelming shortcomings are 
their inability to integrate with surrounding tissues, their inability to become vascularized, and 
their inability to remodel. For these reasons, many investigators have begun to study the 
effectiveness of using tissue engineering techniques (biologically enhanced allografts, cell-based 
therapies, and gene-based therapies) to treat bone defects. 
1.3.1  The Use of Biological Factors to Improve Bone Healing 
Research results continue to support the important role of biologic factors in fracture healing. 
Many biologic interventions are designed to either improve osteoconduction or osteoinduction. 
Osteoconduction is defined as a graft’s ability to act as a scaffold for the ingrowth of native 
bone, which incrementally replaces the graft structure. Osteoinduction is the recruitment of 
osteoprogenitor cells into an osseous defect by bioactive proteins. Typically, osteoinduction 
occurs through the osteogenic differentiation of pluripotent stem cells or through the 
proliferation of already committed pre-osteoblasts. The refinement of currently available 
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treatment modalities will likely rely on improving clinicians’ ability to influence these biologic 
activities. 
No topic in bone healing currently receives more scrutiny than the use of osteoinductive 
agents such as BMPs. The seminal work in this area is Urist's 1965 demonstration of the ability 
of demineralized bone to induce ectopic bone formation [145]. Since that time, many of the 
proteins responsible for bone induction (including BMP2, BMP4, and BMP7) have been 
characterized, cloned, and made available as recombinant human proteins. Recombinant human 
BMPs (rhBMPs) can induce bone formation in many animal models [146-157], particularly 
when allograft substances are delivered along with the BMPs [158-168]. Recombinant BMP use 
is already challenging the gold standard of autologous bone grafting in terms of the ability of 
recombinant BMP to improve bone healing in several human trials involving tibial fracture 
treatment and spinal fusion [169-171]. The widespread use of rhBMP, however, is hampered by 
the large volume of protein required to induce healing comparable to that attained through the 
use of autografts. 
1.3.2 Bone Tissue Engineering 
To improve bone healing after surgical interventions, trauma, or congenital insults, many 
investigators have begun to use gene-based tissue engineering techniques to administer different 
BMPs [172-180]. Many of the reported studies have involved the direct addition of genetic 
material to the bone defect site, a process referred to as “in vivo gene therapy”. When using in 
vivo therapies, researchers must choose the transgene that will evoke the desired effect. Ex vivo 
gene-based therapies involve the addition of genetic material to cells in vitro and the subsequent 
implantation of the genetically altered cells within the defect. The use of ex vivo gene-based 
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therapies necessitates selecting the optimal transgene, choosing a cell population to use, and 
selecting an appropriate scaffold to deliver cells at the site of desired activity. Investigators have 
used many different cell populations in ex vivo gene-based therapies designed to promote bone 
healing, including bone marrow stromal cells [181-187], adipose tissue-derived cells [178, 188-
194], fibrous tissue-derived cells [195, 196], and skeletal muscle-derived cells [172, 197-205].  
1.4 SIGNIFICANCE 
The scientific understanding of the process of bone healing was greatly advanced by Urist’s 
discovery of the bone forming BMPs [145]. Since then, many researchers have been focused on 
means to improve bone healing, often by inducing increased bone volume or by reducing the 
time it takes for bone to form. Although this research has led to some improvements in the 
treatment of large bone defects, there has been little work to translate this research to a clinically 
relevant treatment. Furthermore, as in cases of craniosynostosis, there is a need to develop 
strategies that will inhibit bone formation and avoid rapid reossification of surgical sites. In this 
series of studies, we tested the general hypothesis that the ability of Noggin to inhibit BMPs 
could be used to control the formation of bone within craniofacial defects. The work presented 
here was intended to further the understanding of the regulation of bone formation following 
injury. A more complete understanding of the molecular pathways that can be manipulated to 
inhibit bone formation may also offer insight into means of enhancing bone formation.  
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2.0 NOGGIN INHIBITS RESYNOSTOSIS IN CRANIOSYNOSTOTIC RABBITS 
2.1 INTRODUCTION 
Craniosynostosis is the term given to the premature fusion of one or more of the cranial sutures 
and occurs with an estimated birth prevalence of 300-500 per 1,000,000 live births [2]. Primary 
craniosynostosis causes secondary deformities in the cranial vault, cranial base, and in the 
midface [6, 9, 12, 14, 206] that can cause increased intracranial pressure [15-17, 20, 23, 50] and 
altered intracranial volume [20, 23-25] that can lead to blindness, cognitive deficiencies and 
mental retardation if left uncorrected [16, 20, 27, 29]. Current surgical management involves the 
extirpation of the fused suture along with extensive cranial vault reshaping [31, 33, 41, 43, 44]. 
Although current surgical strategies often allow for normal brain growth and 
development, re-establish normal intracranial volume and pressure, and correct cosmetic 
deformities, the suturectomy site frequently reossifies very rapidly after surgery (in 30%-100% 
of reported cases and as early as 6 months after surgery). Reossification of the suturectomy site 
leads to the reapproximation of the osteotomy margins and the refusion of the extirpated suture, 
termed “resynostosis” [28, 38, 44, 45, 47, 48, 52]. Such resynostosis can lead to a secondary 
increase in intracranial pressure and further restrict craniofacial growth [4, 5, 54], necessitating 
additional surgical procedures [61] and increasing the risk of patient morbidity and mortality. 
The molecular mechanisms underlying resynostosis are poorly understood, though we 
believe that, through an understanding of normal bone healing events, we may be able to 
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successfully inhibit resynostosis following surgical correction of craniosynostosis. The healing 
of bone fractures and surgically created defects has been rigorously investigated. Several bone 
morphogenetic proteins (BMPs) have been extensively studied for their ability to induce bone 
formation, including BMP2, BMP4 and BMP7 [138, 160, 169, 207]. More importantly, BMPs 
have been shown to be expressed during normal bone healing, suggesting their involvement in 
the healing process [208, 209].  
Since BMPs seem to be involved in normal bone healing events, the inhibition of BMP 
signaling may lead to the inhibition of bone formation. Noggin has been identified as an 
extracellular antagonist to BMPs [131, 132] and has been shown to be expressed along with 
BMP4 during normal bone healing [210]. Furthermore, Noggin has been shown to inhibit ectopic 
bone formation when delivered either systemically [211] or locally [212], and has been used to 
inhibit membranous bone healing [213]. 
 In an attempt to develop an adjunct to standard surgical techniques that improves 
postoperative outcomes, we hypothesized that local application of Noggin to the suturectomy site 
would inhibit resynostosis in a well-described rabbit model of human, nonsyndromic coronal 
suture synostosis [9-11, 18, 22, 24, 54, 100, 214]. 
2.2 HYPOTHESIS 
It was hypothesized that Noggin protein treatment would inhibit postoperative resynostosis and 
improve postoperative outcomes in a rabbit model of human nonsyndromic craniosynostosis. 
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2.3 MATERIALS AND METHODS 
2.3.1 Sample 
Thirty-one New Zealand White rabbits with bilateral coronal suture synostosis (Figure 4A) were 
obtained from an ongoing breeding colony of craniosynostotic rabbits housed at the University 
of Pittsburgh [9, 215, 216].  
The rabbits were randomly assigned to three groups as follows: Group 1) Suturectomy 
with no treatment, which served as the surgical control group (n=13); Group 2) Suturectomy 
with non-specific, bovine serum albumin (BSA) in a slow release collagen vehicle, which served 
as the protein control group (n=8); and Group 3) Suturectomy with Noggin protein in a slow 
release collagen vehicle, which served as the treatment group (n=10). This protocol was 
approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. 
2.3.2 Surgical Technique 
Following diagnosis of bilateral coronal suture synostosis, the synostosed coronal sutures were 
extirpated in 10 day old rabbits using a strip suturectomy procedure described previously [54, 
101]. All rabbits were anesthetized with an intramuscular injection (0.59ml/kg rabbit body 
weight) of a solution containing 91% Ketaset (ketamine hydrochloride, 100mg/ml) and 9% 
Rompun (xylazine, 20mg/ml). The scalps were then shaved, depilated, and prepared for surgery. 
The calvaria were exposed by a midline scalp incision, and the skin was reflected laterally to the 
supraorbital borders. Each synostosed coronal suture was identified and a cutting burr was used 
to extirpate a 3mm–wide strip of frontal and parietal bones, including the entire length and width 
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of the coronal suture, in one piece (approximately, 3x15mm defects). Care was taken to preserve 
the meningeal (fibrous) layer of the dura and the regional vascularity.  
In rabbits in the suturectomy control group, only the suturectomy was performed; nothing 
was injected. The periosteal and skin incisions were closed with 4-0 vicryl suture. In rabbits in 
the vehicle/protein control group, a 26G needle was used to inject collagen (0.1ml/suture) that 
was mixed with BSA (Sigma) into the suturectomy site (10µg BSA per defect) (Figure 4B, C). 
 
 
Figure 4: Animal model of craniosynostosis and surgical intervention 
A) Photograph showing the skulls of a normal, wild type rabbit (right) compared to a rabbit with complete bilateral 
coronal suture synostosis. Both skulls were from 84 day old rabbits. Note the lack of a coronal suture in the 
synostosed rabbit (arrow). B) Intraoperative photograph showing the defect resultant from the suturectomy and the 
initial placement of the collagen gel. C) Intraoperative photograph showing the final placement of the injectable 
collagen gel that was either mixed with BSA or Noggin. Note: the injectable nature of the gel allowed for precise 
placement of the treatment within the defect site. 
 
The third group of defects was injected with collagen mixed with Noggin protein (Sigma) 
for a final concentration of 10µg/defect. Next, a fine dental burr (0.5mm) was used to make holes 
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in the periosteum and bone for radiopaque amalgam markers. The holes were placed in 
quadrants, 2mm anterior and posterior to the coronal, frontonasal, and lambdoidal sutures and 
2mm lateral to the sagittal and interfrontal sutures. These holes were packed with silver dental 
amalgam to serve as radiopaque markers for the radiographic analysis of postoperative 
craniofacial growth. All animals received postoperative intramuscular injections (2.5mg/kg of 
rabbit body weight) of Baytril (Bayer Corp., Shawnee Mission, KS).  
2.3.3 Data Collection 
2.3.3.1 Somatic and skeletal growth 
Longitudinal somatic (body weight), skeletal (third right metacarpal length from radiographs), 
and cephalometric growth data was recorded for all rabbits at 10, 25, 42, and 84 days of age. At 
84 days of age, approximately 90% of calvarial [5, 6, 9, 217, 218] and 90% of brain growth [214, 
219] are completed in rabbits. Lateral and dorsoventral radiographs of the head and front right 
paw were taken with the rabbits tranquilized with an IM injection (10 mg/kg) of Ketaset 
(Ketamine hydrochloride, 100 mg/ml). The heads were immobilized in a specially designed 
cephalostat and a Phillips Oralix 70 dental x-ray unit was used at an exposure of 50kV, 7mA, a 
.17 to .50 second exposure time, and a tube-to-cassette distance held constant at 152 cm. Lateral 
and dorsoventral radiographs of the head were viewed on a light box, and the amalgam markers 
and landmarks under study were identified and traced. Craniofacial growth in a number of 
dimensions was assessed, including: amalgam marker separation at the coronal suturectomy site; 
craniofacial length; and cranial vault shape. All measurements were taken blind as to rabbit 
group identity and intra-observer, repeated measurement reliability was calculated 
(r=0.901;p<0.01) on a randomly drawn sample (10%) of rabbit cephalographs. 
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2.3.3.2 Suturectomy site healing and intracranial volume 
Serial computed tomographic (CT) scans of the rabbit heads were obtained at 10, 25, 42, and 84 
days of age. A GE HiSpeed Advantage Scanner (DFOV = 24.0-18.0cm; mA = 120–150; kV = 
120) was used at a thickness of 1mm to scan heads in the sagittal plane. The boundaries of the 
suturectomy sites were automatically traced, the healing defect site reconstructed in three 
dimensions, and the defect areas calculated. The endocortical boundaries of the cranial vault 
cavities were also traced both automatically and manually and reconstructed in three dimensions. 
Finally, the indirect intracranial volume (ICV) of each animal at each time point was calculated. 
All calculations were performed with Allegro Software (ISG Technologies, Atlanta, GA) on a 
Sun Workstation. All measurements were taken blind as to rabbit group identity and intra-
observer, repeated measurement reliability was calculated (r=0.936;p<0.01) on a randomly 
drawn sample (20%) of the rabbit 3D-CT scans.  
2.3.4 Statistical Analysis 
Means and standard deviations for suturectomy site areas, ICVs, body weights, third metacarpal 
lengths, and the craniofacial measurements were calculated and compared among groups using a 
3 x 4 (group by age) two-way analysis of variance (ANOVA) with an unweighted means 
analysis. Significant intergroup differences at each age were assessed using the Least Significant 
Differences multiple comparison test. The relationship between defect area and ICV at different 
ages was also assessed using Pearson product moment correlations. All data were analyzed using 
SPSS 12.0 for windows (SPSS, Inc., Chicago, IL). Differences were considered significant if p < 
0.05. 
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2.3.5 Histological Analysis 
At 84 days of age, all rabbits were euthanized by intravenous injection of pentobarbital 
(300mg/kg rabbit body weight), and the defects harvested for histological examination. The 
specimens were fixed, demineralized in 10% EDTA, and processed for paraffin sectioning. The 
specimens were then sectioned in a sagittal plane in the middle of both the right and left coronal 
sutures at a thickness of 5µm. Sections were stained with hematoxylin and eosin for qualitative 
histological description. 
2.4 RESULTS 
2.4.1 Somatic Growth 
Mean body weight in all three groups changed in a linear fashion across age (Figure 5A). 
Significant group (F=5.83;p<0.01) and age (F=586.54;p<0.001) main effects were noted. No 
significant group x age interaction effects (F=1.20;NS) were seen. Multiple comparison tests 
revealed that BSA treated rabbits were significantly (p<0.05) heavier than the other two groups 
at 42 days of age (Figure 5A). Mean metacarpal length increased in a curvilinear fashion in all 
three groups (Figure 5B). A significant age main effect (F=161.42;p<0.001) was noted. No 
significant group (F=1.83;NS) or group x age interaction effects (F=0.61;NS) were seen. 
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 Figure 5: Somatic growth results 
A) Graph showing the changes in body weight over time (±SEM). Note: there were no significant differences in 
body weight. B) Graph showing third metacarpal length over time (±SEM). No significant differences were found 
between groups. 
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2.4.2 Cephalometric Analysis 
Lateral cephalographs at 84 days of age show still patent suturectomy sites, widened 
coronal suture amalgam markers, and slightly altered craniofacial skeletons in Noggin treated 
rabbits compared to the two other groups (Figure 6).  
 
Figure 6: Lateral cephalographs of select rabbits 
Lateral cephalographs were used to measure the separation of radioopaque markers placed in the calvaria at the time 
of suturectomy (10 days of age). Note that the Noggin treated (NOG) rabbits showed large areas of radiolucent 
defects even at 84 days of age (arrows) compared to suturectomy control (SC) and BSA-treated (BSA) animals. 
 
 
 23 
Analysis of mean coronal suture marker separation revealed that Noggin treated rabbits 
had greater marker distances at all postoperative intervals compared to both control groups 
(Figure 7A). Statistical analysis revealed significant group (F=7.00;p<0.001) and age 
(F=23.38;p<0.001) main effects. No significant group x age interaction effect was noted 
(F=0.98;NS). Multiple comparison tests revealed that coronal suture marker separation in 
Noggin treated rabbits was significantly (p<0.05) greater than suturectomy controls or BSA 
treated control rabbits at all three postoperative ages (Figure 7A). No significant difference in 
mean marker separation was noted between suturectomy controls or BSA treated rabbits at any 
age. Mean craniofacial length in all three groups changed in a curvilinear fashion across age 
(Figure 7B). Significant group (F=2.39;p<0.05) and age (F=369.73;p<0.001) main effects were 
noted. No significant group x age interaction effect (F=0.81;NS) was seen. Multiple comparison 
tests revealed that Noggin treated rabbits had significantly (p<0.05) greater craniofacial lengths 
than suturectomy controls or BSA treated rabbits only at 84 days of age (Figure 7B). Mean 
cranial vault shape indices decreased in a curvilinear fashion in all three groups over time 
(Figure 7C). Noggin treated rabbits showed greater indices than the other two groups at all three 
postoperative times. However, only a significant age main effect (F=23.72;p<0.001) was noted. 
No significant group (F=0.59;NS) or group by age interaction effects (F=0.70;NS) were seen. 
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 Figure 7: Cephalometric data 
A) Coronal suture marker separation (±SEM) shows that Noggin treated defects allowed for significantly increased 
marker separation compared to suturectomy and BSA treated defects. B) Mean craniofacial length (±SEM) was 
increased in Noggin treated animals at 84 days of age compared to suturectomy and BSA treated controls. C) 
Cranial vault shape indices (±SEM) were found to be greater in Noggin treated animals. Analysis revealed that the 
differences were not significant. 
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2.4.3 Computed Tomographic Analysis 
Suturectomy sites in both suturectomy control rabbits and rabbits treated with BSA showed rapid 
reossification through 84 days of age, as seen on the 3D-CT scan reconstructions (Figure 8A). In 
contrast, suturectomy sites in rabbits treated with Noggin increased in size at 25 days of age and 
were more patent at 84 days age (Figure 8A). Mean suturectomy site area in both suturectomy 
control rabbits and rabbits treated with BSA showed similar reossification rates which decreased 
to approximately 30% of the original defect area by 84 days of age (Figure 8B). In contrast, 
mean suturectomy site areas in rabbits treated with Noggin increased to approximately 120% of 
original defect size at 25 days of age and had approximately 60% of the original defect area 
remaining at 84 days of age (Figure 8B). It is interesting to note that suturectomy site areas in 
Noggin treated rabbits paralleled the two other control groups from 25 to 84 days of age (Figure 
8B). Statistical analysis revealed significant group (F=23.29;p<0.001) and age 
(F=31.75;p<0.001) main effects. No significant group x age interaction effect was noted 
(F=0.19;NS), showing that defect area was changing in a parallel fashion among groups over 
time between 25 and 84 days of age. Multiple comparison tests revealed that Noggin treated 
defects were significantly (p<0.05) larger than suturectomy controls or BSA treated control 
defects at all time points after surgery (Figure 8B). No significant differences in mean defect 
area were noted between suturectomy controls or BSA treated rabbits at any age. 
 ICV in all three groups showed similar curvilinear changes from 10 to 84 days of age 
(Figure 8C). Noggin treated rabbits had greater ICVs from 25 to 84 days of age (Figure 8C).  
Statistical analysis revealed significant group (F=5.15;p<0.01) and age (F=180.74;p<0.001) main 
effects. No significant group x age interaction effect was noted (F=1.30;NS), showing that ICV 
was changing in a parallel fashion among groups over time. Multiple comparison tests revealed 
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that ICV in Noggin treated rabbits was significantly (p<0.05) greater than suturectomy controls 
or BSA treated control rabbits only at 84 days of age (Figure 8C). No significant differences in 
mean ICV were noted between suturectomy controls or BSA treated rabbits at any age. The 
relationship between percent defect area and ICV was assessed within groups at all three 
postoperative ages. Noggin treated rabbits had positive correlation coefficients at 25 (r= 
0.30;NS), 42 (r=0.68;p<0.05), and 84 days of age (r=0.33;NS). In contrast, suturectomy controls 
(25 r= -0.48;NS, 42 r=-0.45;NS, and 84 days of age r=-0.33;NS) and BSA treated rabbits (25 r= -
0.35;NS, 42 r=-0.61;NS, and 84 days of age r=-0.03;NS) had negative correlation coefficients at 
all three postoperative ages. 
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 Figure 8: CT reconstructions and defect healing data 
A) 3D reconstructions of serial CT scans performed on suturectomy control, BSA treated, and Noggin treated 
rabbits at 10, 25, 42, and 84 days of age. Noggin seemed to inhibit healing of suturectomy sites. B) Analysis of 
defect area (±SEM) showed that Noggin treated defects were significantly larger at every time point after surgery 
(25, 42 and 84 days of age).  C) 3D analysis of intracranial volume (±SEM) showed that Noggin treatment increased 
intracranial volume significantly at 84 days of age. 
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2.4.4 Histological Analysis 
Qualitative microscopic analysis revealed that, at 84 days of age, the suturectomy control group 
had nearly complete wound healing, with extensive reossification and resynostosis of the 
suturectomy sites (Figure 9, Suturectomy control). In this control group, most of the original 
suturectomy sites were completely obliterated (Figure 9, Suturectomy control). The BSA 
treated defects showed incomplete wound healing with some bony bridging.  Most sections 
demonstrated some fibrous tissue within the suturectomy site (Figure 9, BSA). The Noggin 
treated defects showed incomplete wound healing, with large regions of fibrous tissue within the 
defect (Figure 9, Noggin). 
 
 
Figure 9: Histology at 84 days of age 
Histological analysis revealed that suturectomy control and BSA treated defects showed almost complete defect 
healing at 84 days of age, whereas Noggin treated defects showed large areas of fibrous tissue within the defect at 84 
days of age. This qualitative data supports the radiographic data showing larger, unhealed defects in the Noggin 
treated group compared to the other groups. 
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2.5 DISCUSSION 
Craniosynostosis can result from several identified genetic mutations, including FGFR1, 
FGFR2, MSX, and TWIST. For the nonsyndromic craniosynostoses, the genetic and/or epigenetic 
causes remain largely unknown. Much of the recent research in craniosynostosis has centered on 
the elucidation of the molecular mechanisms that lead to either normal [82, 87, 97, 220, 221] or 
premature [62, 68, 98, 222] suture fusion. This line of research has led to a better understanding 
of the complexity of the molecular interactions that regulate bone formation and suture 
development and maintenance, though it has not, as yet, been used to develop biologically-based 
therapies to reduce the occurrence of postoperative resynostosis or to improve surgical outcomes. 
One correlate that is common to all types of craniosynostoses, regardless of genetic or 
environmental cause, is an overgrowth of bone. Normal sutures remain patent, or devoid of bony 
bridging, to allow for the growth of the developing brain. The fusion of sutures occurs by the 
ossification of the normally patent suture through the process of osteogenic differentiation. We 
believe that the regulation of bone overgrowth should be the target of any therapy developed to 
improve treatment of craniosynostosis if a single therapy is to be useful to all patients presenting 
with craniosynostosis. Because BMP2, -4, and -7 have been found to be potent bone-inducing 
proteins that are expressed during normal bone healing [209], we hypothesized that BMP 
function may be instrumental in the occurrence of resynostosis in a rabbit model of human non-
syndromic craniosynostosis. Noggin was chosen to test our hypothesis because of its ability to 
inhibit the activity of BMP2, -4, and -7 [131, 132, 223].  
We found that Noggin treatment was effective in inhibiting bone healing and delaying 
suturectomy site resynostosis in the rabbit model, evidenced by the long-term persistence of 
defects in the calvaria up to 84 days after treatment. The data also suggest that Noggin, delivered 
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once, within a slowly resorbing collagen gel, can have long term effects on craniofacial growth 
in this model. There was an initial increase in the size of the suturectomy site in the Noggin 
treated group. We believe that this increase is because, after the surgical release of the fused 
suture, the brain begins to expand in the anteroposterior direction. Though this brain expansion 
may also be occurring in the BSA and untreated control groups (evidenced by the similar ICV 
measurements at 25 and 42 days of age, Figure 8C), the amount of bone healing obscures this 
fact.  
The inhibition of bone healing by Noggin therapy occurred primarily in the first 15 days 
after surgery (up to 25 days of age), followed by the resumption of bone healing at rates similar 
to control defects. Notice that the graph of reossification (Figure 8B) shows that lines 
connecting 25, 42, and 84 days in the Noggin treated group closely parallel the lines in the two 
control groups. The only difference between these lines is that the Noggin treated group shows 
an increase in defect size between 10 and 25 days of age, starting their normal healing from a 
different defect size than the two control groups. We believe that the resumption of normal 
healing after 25 days of age in the Noggin treated group reflects the loss of Noggin function due 
to its release from the collagen gel over time. Although the protein was added to a slowly 
resorbing collagen gel, we believe that most of the protein releases from the gel over the first two 
weeks in vivo. This would account for the normal healing that is noticed after 25 days of age (15 
days after surgery). This hypothesis regarding the 15 day duration of Noggin activity is also 
supported by the marker separation data. We find that the markers in the Noggin treated group 
are significantly farther apart at 25 days of age compared to the control groups, and not 
significantly different at the later time points. We believe that the marker separation data reflects 
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the occurrence of resynostosis (healing) along the lateral aspects of the defects, causing a 
reduction in the rate of marker separation. 
Although the protein may have had limited temporal activity, the data presented here 
show that a single dose of Noggin can have lasting effects on defect healing and improve ICV 
and craniofacial growth in synostotic rabbits almost to levels similar to wild-type rabbits. In 
rabbits, 90% of the total brain growth is completed by 84 days of age [214, 219]; whereas, in 
humans, it takes nearly 6 years to complete 90% of brain growth [1]. Therefore, therapies 
developed for use in humans must have a much longer period of effect than those studied in our 
rabbit model of simple, nonsyndromic craniosynostosis. For this reason, our group is working on 
testing several delivery mechanisms for protein-based and gene-based therapies. 
We believe that Noggin-based therapy may represent a particularly useful means for the 
inhibition of postoperative resynostosis for two reasons. First, Noggin therapy, similar to any 
biologically-based adjunct to surgery, may improve surgical outcomes while at the same time 
allow for minimal surgical intervention. We envision that small craniectomies, placed where 
sutures normally exist, will be able to remain patent by inhibiting bone formation in that region 
using Noggin-based therapies, thus allowing for more normal brain and craniofacial growth 
postoperatively. Second, by targeting BMP signaling, we may be able to sidestep the direct 
molecular cause of the original synostosis. BMPs are potent inducers of bone formation. 
Interruption of BMP signaling should inhibit the osteogenic differentiation of cells regardless of 
their genetic background. Though much work needs to be done with respect to understanding the 
role of BMPs in craniosynostosis, their role in bone healing is well understood. We feel that the 
inhibition of BMP signaling may be the upstream event that can nullify many of the downstream 
events that are associated with the known mutations that lead to craniosynostosis. Most 
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importantly, this study showed that Noggin treatment may have some effect on the abnormal 
healing patterns that are exhibited by individuals (both rabbit and human) with craniosynostosis. 
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3.0 DEVELOPMENT OF A MODEL FOR CRANIOFACIAL BONE REGULATION 
3.1 INTRODUCTION 
The second chapter of this dissertation showed that a therapy using a natural inhibitor to BMPs 
can have lasting effects on surgical outcomes. This work was undertaken to try and reduce the 
occurrence of the clinically relevant problem of postoperative resynostosis in craniosynostotic 
children. The results of the protein therapy in craniosynostotic rabbits showed that mixing 
Noggin protein with a slowly resorbing collagen gel had an approximate 15 day temporal effect. 
Though the Noggin therapy had long-term effects on the intracranial volume in treated animals, 
the defects seemed to heal normally after about 15 days after surgery. Therefore, the effect of 
this type of “one-shot” treatment was shown to be about 15 days.  
In order to better understand the possible effects of long-term Noggin treatment on bone 
healing, we had two choices. The first was multiple dosing of the rabbits with Noggin. Repeated 
injection of Noggin at different times after surgery would allow for a determination of the effects 
of extended Noggin exposure on defect healing. Such a strategy would, however, necessitate 
multiple surgeries on each animal and run a higher risk of infection (multiple interventions). 
Therefore, we decided to utilize a tool developed by Dr. Hairong Peng in the laboratory of 
Johnny Huard [212] to test the effects of longer-term Noggin treatment on calvarial defect 
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healing through the transduction of muscle-derived cells with a retroviral vector encoding 
Noggin expression. 
The vast majority of the research that has been done on bone healing and bone formation 
relates to the improvement of large defect healing. In order to pursue the study of bone 
regulation, it was necessary to identify a reliable animal model. The goal of this aspect of my 
research was to test the effects of Noggin treatment on the regulation of normal bone healing in a 
mouse model. It was necessary to create a model of bone healing in the rodent that would 
simulate the molecular events that occur during resynostosis following surgical intervention to 
correct craniosynostosis. This model would need to have three key characteristics: 1) it would be 
a calvarial bone defect; 2) it would heal reproducibly; and 3) it would show significant healing 
within a short period of time. 
There are very few standardized calvarial defect models. The most widely used and well-
defined is the critical size defect, or CSD. A CSD was defined by Schmitz and Hollinger as “the 
smallest size intraosseus wound in a particular bone and species of animal that will not heal 
spontaneously during the lifetime of the animal” [224]. This animal model of human bone defect 
nonunion was proposed as a way to standardize research models for bone repair materials [224, 
225]. Since the introduction of the term, CSDs have been used routinely in many laboratories to 
test the osteogenic capacities of different bone repair techniques (for review, see Mooney and 
Siegel, 2005 [226]). We believed that a minor modification of the CSD would yield new model 
for craniofacial bone healing. 
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3.2 STRATEGY 
3.2.1 Defect Size 
Mouse calvarial CSDs are defined as 5mm round defects [199, 226, 227]. The first variable that 
we manipulated to try and create a non-critical size defect was the defect size. We were 
confident that defects smaller than 5mm in diameter would consistently heal in a relatively short 
period of time because CSDs were defined as the “smallest” defects that would not heal. To test 
this hypothesis, we created sub-critical size defects using 1.8mm outer diameter trephines (Fine 
Science Tools), in 10 week old normal (C57BL-6J, Jackson) mice. At the time of surgery, the 
trephines were used to make unilateral, bicortical, mid-parietal defects. The 1.8mm trephine was 
chosen because it was the smallest commercially available trephine. We analyzed healing of 
these mice radiographically using 2-dimensional defect area analysis 6 weeks after surgery 
(Figure 10A), expecting to find that the calvarial defects we created were significantly healed. 
However, in the 10 animals in this study, we found large defects still remaining with an average 
of approximately 43.3% healing after 6 weeks (Figure 10B) 
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 Figure 10: Analysis of untreated mouse 1.8mm calvarial defects 6 weeks postoperatively 
A) Radiograph showing remnant defect in mouse calvaria 6 weeks after creating a 1.8mm outer diameter defect. 
Yellow dashed circle shows the outline of the original defect. B) Graph showing the 2D measurement of bone 
formation (±SEM) within the defect after 6 weeks. 
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 This data demonstrated that defects much smaller than critical size do not readily heal in 
the adult mouse calvaria. One possible reason for this inability to heal was the technique. The 
trephine burr is known to easily damage the underlying dura mater as soon as it cuts through the 
endocortex of the calvaria (anecdotal evidence). The next most logical variable to manipulate 
was the surgical technique used to make the defect. 
3.2.2 Surgical Technique 
It is well known that the dura mater plays a significant role in the healing of calvarial defects [47, 
228-232]. The dura mater seems to be both the primary source of osteogenic cells and the source 
of osteoinductive factors during calvarial wound healing [233]. The surgical technique 
employing a trephine may have damaged or destroyed the dura mater underlying the defect, 
thereby inhibiting defect healing. 
 In order to eliminate the possibility of dural damage, a set of experiments was designed 
with the assistance of Dr. Joseph E. Losee, a pediatric craniofacial surgeon who performs similar 
surgery routinely in infants with craniosynostosis. This experiment compared the healing among 
three groups of animals with defects created in different ways. In the first group of animals, we 
used a trephine to create the bicortical defect, paying particular attention to preserving the dura 
mater (“trephine” group). In the second group of animals, we used the trephine, but deliberately 
damaged the dura mater to ensure disruption of the dural component (“dural damage” group). In 
the third group, we performed surgery a bit differently. First, we used the 1.8mm trephine to 
score the parietal bone and cut through the ectocortex and some of the endocortex. A small 
otoelevator was then used to break through the remaining endocortex and to remove the bone 
from the defect (“elevator” group). This technique allowed us to preserve the dura mater (Figure 
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11A) and create a defect that was 1.8mm in diameter at the ectocortex; however, the technique 
also led to a defect with a variable diameter along the endocortex, because the bone was 
fractured instead of cut in this region (Figure 11B). 
 
 
Figure 11: Intraoperative photograph of defect created using the “elevator” technique 
A) Photograph of defect created by fracturing through the endocortical layer of the parietal bone. The undamaged 
blood vessels within the defect (arrows) demonstrated that the dura was left intact. B) Same picture as in A with an 
outline of the endocortical defect margin. Notice that the margin is not uniform because of the fracturing technique 
that was used in the elevator group. 
 
 
 Animals in this study were killed 4 weeks, 8 weeks, and 1 year after surgery and healing 
of the parietal defects was assessed radiographically. Defect area was calculated using Northern 
eclipse software and statistical analysis was performed with SPSS. Statistical analysis showed 
that the elevator group healed more than the trephine group at both 4 (Figure 12A) and 8 weeks 
(Figure 12B) after surgery. Analysis of radiographs after 1 year of healing (Figure 12C,D) 
showed that defects created using the elevator technique were 52% filled by bone, whereas the 
trephine and dural damage groups healed no more than 35% of the defect (p=.257). 
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 Figure 12: 2-Dimensional radiographic analysis of surgical technique effect on defect healing 
A) Graph showing the mean (±SEM) area of new bone formation within defects 4 weeks after surgery. The trephine 
group healed approximately 26% while the elevator group healed approximately 35% after 4 weeks. B)  Graph 
showing defect healing 8 weeks after surgery at which time the trephine group had healed approximately 25% 
compared to nearly 50% healing in the elevator group. C) Radiographs showing the initial defects (day 0) and 
healing at 1 year for all groups. D) Graph showing the mean (± SEM) of defect healing in all groups 1 year after 
surgery. After 1 year, the trephine group only healed about 35% of each defect, and the elevator group healed 
approximately 52%. As shown in D, dural damage group healed similarly to the trephine group at all times (not 
shown). 
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 These results suggest that the surgical technique alone did not significantly influence the 
healing of small parietal bone defects in normal mice. Specifically, our hypothesis that the lack 
of significant healing could have been due to damage to the dura mater during surgery was not 
supported by this data. The presence of intact, undamaged dura mater in these 1.8mm defects did 
improve the defect healing, but not significantly, and did not lead to complete healing in any 
animal tested. Therefore, we focused on the effect of animal species on the healing of small 
calvarial defects. 
3.2.3 Model Species 
The rat calvarial model is larger than the mouse, and the critical size defect for the rat is 8mm 
[224]. We used a 2.3mm outer diameter trephine to make small calvarial defects in adult 
Sprague-Dawley (SD) rats and allowed the rats to heal for 6 weeks. This experiment was used to 
test the hypothesis that a small calvarial defect created in rats would heal completely in a short 
amount of time. Six weeks after surgery, we killed the rats, removed the brain from the skull, and 
tested defect healing using radiographic analysis. 
 Radiographs showed that 2.3mm defects in the parietal bone of SD rats did not heal 
completely after 6 weeks (Figure 13A). In fact, analysis showed that defects healed 
approximately 36.9% (Figure 13B). 
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 BA 
Figure 13: Rat parietal bone defect healing 6 weeks postoperatively 
A) Radiograph showing the defect remaining after 6 weeks of healing. Notice that most of the healing occurred 
around the perimeter with small islands of bone forming within the defect. B) Analysis of remaining defect area 
(±SEM) determined that these defects healed approximately 37% of the original defect area (2.3mm diameter = 
4.155mm2 area) after 6 weeks. 
 
 These data show that we were unable to achieve the large-scale, rapid healing of a small 
calvarial defect by changing the species to rat. We hypothesized that the choice of strain of rat 
may effect healing. A small study was performed by creating 2.3mm defects in the parietal bones 
of SD, Lewis, and Fischer 344 rats. That study showed that none of the defects in any of the 
strains was able to heal significantly in 6 weeks. 
 Although the rat was believed to be a robust bone-forming animal model, the data 
presented above shows that small defects made in the rat parietal bone do not meet the criteria 
that we needed for a new model of craniofacial bone healing.  
3.2.4 Defect Placement 
The data presented above show that we were unable to create a model of normal craniofacial 
bone healing by decreasing the size of the defect below the “critical” size, by changing the 
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surgical technique to ensure the preservation of the dura mater, or by changing the animal 
species from mouse to rat. Another variable that we could manipulate to try and create the 
desired model was the placement of the defect on the skull. All of the defects described above 
were made within the parietal bone. Identification of an optimal site for creating a defect would 
increase the likelihood of defect healing.  
 In addition to more rapid defect healing, we also hoped to model resynostosis following 
suturectomy surgery in craniosynostotic patients. The perfect model for postoperative 
resynostosis is the rabbit model of human, nonsyndromic craniosynostosis as described above [9, 
11, 24, 25, 54, 100, 137, 215, 216, 234]. However, the rabbit model is more expensive to breed 
and to house and the occurrence of bilateral coronal suture synostosis in this model is low 
enough that large-scale studies (<50 animals) may take a few years to complete. Furthermore, it 
would be extremely difficult to test the effects of a regenerative strategy for rabbits that included 
using multipotent cells because very little work has been done on the characterization of rabbit 
stem cells or their use for gene-based therapies. 
 The most logical site to make a defect that may model resynostosis is at a fused suture. A 
defect created in a naturally fused suture would model the removal of the prematurely fused 
suture (suturectomy). In rodents, there is only one suture that fuses normally early in life. It is the 
interfrontal suture [84-88, 235]. The interfrontal suture has been shown to fuse by 55 days of age 
in mice and by 35 days of age in rats (Figure 14) [84-88, 235]. 
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 Figure 14: Radiograph of 10 week old mouse calvaria 
Radiograph showing parietal bone (PB) and frontal bone (FB) with intervening coronal suture (CS) in a 10 week old 
C57BL/6J mouse. Between right and left frontal bones is the interfrontal suture (IS). The region of the interfrontal 
suture circled in red represents the naturally occurring fusion of the right and left frontal bones. 
 
 In addition to testing the placement of the defect, we also wanted to model a small-scale 
surgical intervention, so we hoped to create the smallest defect possible. We used a cutting burr 
with a much smaller diameter (0.5mm) than any trephine that was available (1.8mm) attached to 
a hand engine (set to 2000 rpm) to create a defect in the posterior interfrontal suture region (the 
region that is fused) in 10 week old C57BL/6J mice (Jackson, USA). We compared these defects 
(n=12) with defects made with the same cutting burr in the middle of the parietal bone to control 
for technique. We killed mice for radiographic analysis immediately postoperatively (n=3), 6 
weeks (n=3), or 12 weeks (n=3) after surgery. 
 Immediately after surgery, the interfrontal defects were highly variable in their size and 
shape as evidenced by radiography (Figure 15, Day 0). Three and 6 weeks after surgery, marked 
healing was evident in all the defects (Figure 15), but small defects still persisted in most of the 
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animals. However, by 12 weeks after surgery, we found that all three of the defects analyzed 
were completely healed (Figure 15). Most importantly, we found that there was no evidence of 
new suture formation in the defect region. This type of healing seemed to model the events that 
occur during resynostosis; namely, a fused suture that was surgically removed healed completely 
and resynostosed. 
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Figure 15: Radiographs of calvaria after novel interfrontal suturectomy surgery 
Radiographs taken of mouse calvaria after animals were killed and the brain removed, anterior is toward the bottom 
of the page. The radiographs show that the initial defect (Day 0) is variable in its size, shape, and area (n=3). All 
defects analyzed 3 (n=3) and 6 weeks (n=3) after surgery showed some level of healing. By 12 weeks after surgery, 
all animals showed complete healing of the defect with no evidence of new suture formation (n=3). 
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 We also tested the healing of linear defects created in the parietal bone using the same 
0.5mm diameter dental burr to test whether the healing we observed was simply due to the 
smaller size of the defect. We observed incomplete healing of the small 0.5mm width defect 
even after 12 weeks postoperatively (Figure 16). These data suggest that the healing of small 
defects is dependent on the placement of the defect, rather than the initial size of the defect 
because small defects created in the interfrontal suture tended to heal, while defects created in 
the parietal bone did not heal well.  
 
 
Figure 16: Radiographs of 0.5mm parietal defects 
Radiographs showing an initial parietal defect (Day 0) and a defect after 12 weeks of healing (12 wk). Note the 
incomplete healing even after 12 weeks. 
 
This data represents the first evidence that we were able to create a small calvarial defect 
modeling a suturectomy that would heal well and model postoperative resynostosis. 
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3.3 DISCUSSION 
3.3.1 Critical Size Defects 
3.3.1.1 The original “critical size defects” 
Despite great strides in our understanding of the molecular and mechanical mechanisms behind 
bone wound healing, very few changes have been made to the clinical treatment of large bone 
defects. Research on bone replacement and bone regeneration has shown that a therapy involving 
an osteoconductive scaffold, osteogenic cells, and an osteoinductive factor (often delivered via 
gene therapy) can impact healing [236]. In general, most of this research is interested in creating 
the largest amount of bone in the shortest amount of time. Unfortunately, in cases of bone 
overgrowth, such as craniosynostosis, it is necessary to control bone formation. For this reason, 
there is a need to develop means to regulate the amount of bone that regenerates following 
surgical damage. To test such regulatory strategies, it was necessary to develop a model of 
normal bone healing. 
The concept of the critical size defect (CSD) was created as a model of nonunion that 
could be used by researchers to test bone replacement materials (BRM) in a consistent manner 
[224, 225, 237]. The need for such a standardized defect came from the practice of researchers 
using many different surgical procedures to test their BRM of interest [224]. CSDs were used for 
two decades to test BRMs, cellular therapies, and other bone replacement strategies. Because 
CSDs were the only standard craniofacial bone defect model, we hoped to use it as a basis for the 
development of a novel model of craniofacial bone healing. 
The CSD, at its inception, was defined as “the smallest size intraosseus wound in a 
particular bone and species of animal that will not heal spontaneously during the lifetime of the 
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animal” [224]. CSDs were developed to model fibrous nonunions in humans. These nonunions 
are not capable of healing without medical assistance. Therefore, the goal was to create a defect 
in animals that would be “shut down” and unable to heal, similar to human nonunions.  
In an attempt to define the difference between “in the process of healing, but not healed 
yet” and “shut down and never going to heal,” Schmitz, et al. attempted to characterize the 
pattern of healing within rat critical size defects by comparing the temporal microscopic healing 
of the CSD (8 mm) over 4 weeks [237]. As a control, the microscopic healing of 3mm and 4mm 
defects was observed. In that study, “no differences in patterns of bone formation and fibrous 
scar tissue formation were observed between the smaller and larger defects” and “none of the 
defects healed completely during the experimental period” [237]. Schmitz, et al. did not find any 
differences between CSDs and smaller defects at 4 weeks other than finding more bone in the 
smaller defects. This study also did not look at the healing of the defects at the end of the 
animal’s natural lifetime. Since there was no microscopic differences observed between “shut 
down” CSDs and “not healed yet” smaller defects, there may be no difference at all, save the fact 
that one is larger than another. 
There is an intuitive difference between the biology of a bone defect that is healing but 
has not completely healed and the biology of a defect that has filled with fibrous tissue and will 
never heal. Clinically, the term “nonunion” is given to a defect that is not healed within 8 months 
of injury [238], but the decision to intervene surgically is mainly up to the individual clinician. 
This clinical definition that employs an 8 month “cut-off” point can be altered, based on the 
discomfort of the patient. A surgeon can initiate intervention or wait longer to see if a bone 
defect will heal, depending on whether the patient is in pain or debilitated. It is important to 
notice that the definition of a CSD, which is supposed to be a model of human nonunion, is 
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based on the size of the defect that will not heal within the lifetime of the animal. There is no 
direct clinical correlate to the CSD defined in this way because such a definition would depend 
on outcomes measured at the death of the patient.  
More importantly, there seems to be no clinical relevance to the CSD not healing. In 
orhopaedic reconstruction, after a nonunion is diagnosed, surgery is performed to debride the 
defect and create, basically, a new bone defects that can be treated by whatever means the 
surgeon deems useful, usually bone autograft. At no point is the nonunion or the fibrous tissue 
that fills a CSD treated directly. In reconstruction of the calvaria, the dura mater underlying the 
defect often becomes scarred and calcified. This tissue cannot be disturbed to avoid causing a 
dural tear. Though the translation of a defect that is “shut down” does seem to apply to the 
clinical reality of calvarial defects, no research has yet been performed to test therapies to heal 
CSDs that were already filled with fibrous tissue. Because of the weak clinical applicability, and 
the lack of experimental backing for the biological relevance, the definition and use of CSDs 
must be amended. 
3.3.1.2 Re-defining “critical size defects” 
A few researchers have found that the original definition of CSD is not really functional. Gosain 
et al. stated that “A critical-size defect is one that will not heal within the lifetime of the animal. 
However, because most studies are of limited duration and do not extend over the entire life of 
the animal, the critical-size defect in animal research refers to the size of a defect that will not 
heal over the duration of the study” [239]. This new definition dropped the idea of “smallest 
interosseus defect” and the dependence on the “lifetime of the animal.”  
 There are several theoretical issues with altering the definition of “critical size” that have 
not been discussed in the literature. First, Gosain et al. state that “the critical-size defect in 
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animal research refers to a defect that will not heal over the duration of the study” [239]. In fact, 
critical size defects are only defined in animal research. The clinical term is nonunion, and is 
defined as stated above [238]. Therefore, it is incorrect to state that critical size is defined 
differently for animal research than for an animal model. 
 Second, this re-definition undermines the attempt to standardize bone healing research. 
When employing the new definition of critical size as not healing within the duration of the 
study, the definition hinges on the length of the study, not the surgical model. If someone creates 
a very small fracture or defect, and looks for healing in a very short time (one hour, for 
example), should the small defect be considered critical size? If the answer is yes, then there is 
no point to defining “critical size defects” in order to standardize research practices because each 
researcher can utilize his or her own defect to test bone healing strategies. 
 Third, the CSD theoretically models the nonunion by simulating a defect that is “shut 
down” and will never heal. By changing the definition to a defect that will not heal over the 
course of the study, we lose the concept that the biology might be different for non-healing 
defects than it is for normally healing or slowly healing defects. Therefore, this re-definition also 
undermines the attempt to model human nonunions. 
3.3.1.3 Technology and “critical size defects” 
Analytical techniques go hand-in-hand with the choice of model. Our means to analyze bone 
growth and regeneration are improving through technological advances. Our use of experimental 
models must change to utilize the new technologies. Common techniques to analyze bone 
formation include histological bone area measurement or assessment of radiographic area or 
radiodensity measurements. These techniques are useful for the identification of bone formation 
but are less useful when comparing different treatments (to obtain a quantitative measurement of 
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bone formation) due to the fact that these analyses change three dimensional data into two 
dimensional data. Radiodensity can be used as a general indicator of the mass of the formed bone 
in that more bone in a region will be more opaque. However, high radiographic density may be 
caused by the superimposition of poorly organized bone. Therefore, it is difficult to interpret the 
quality of bone formation from radiographic evidence.  
Similarly, histological analysis can only consider the quantitative measurement of bone 
area within a 2-dimensional cross section and the qualitative morphology of the bone. Area 
measurements cannot be directly compared between treatment groups because the morphology 
must be considered. For example, a region of many small trabeculae may have a larger measured 
bone area than a thin sheet of cortical bone. It is difficult, with this information, to determine 
which one is “better.” Gosain et al., after re-defining critical size, attempt to assist researchers to 
more accurately measure the amount of bone that forms within a critical size defect [239]. Their 
suggestion was to measure the area of bone within the defect through histological evaluation, 
rather than a linear measurement if defect healing. Fortunately, technology has improved to 
allow for the accurate quantification of the volume of bone within a defect. Bone volume is 
much more accurate than a gross estimation of 2-dimensional bone area taken from a histological 
cross-section, the area of which is dependent on the angle of the bone when the slide is cut. 
Bone volume and its complimentary defect volume can be measured in live animals using 
micro computed tomography (µCT). Because of the limitations of traditional analytical 
techniques, many investigators are utilizing computed tomography to improve their 
analyses[166, 174, 179, 182]. CT analysis allows for the quantification of bone mineral density 
[179, 240, 241] and bone mineral content [174, 242] within the newly formed bone. The use of 
CT for these types of analyses allows investigators to quantify the opacity of bone in thin slices 
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of the area of measurement (often 1mm) versus a radiographic, 2-dimensional, picture that 
encompasses the entire bone mass. With the advent of micro computed tomography (µCT), 
investigators are able to make the same measurements of bone density and mineral content from 
extremely thin slices through the region of interest (5-100 µm). Also, by using any type of CT, 
one can generate 3-dimensional images of the newly formed bone. Similar to the use of histology 
to assist radiographic analysis, µCT-generated morphological data can be used to strengthen 
interpretations of the quality of bone formation (see Figure 17).  
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 Figure 17: Comparison between radiographic and µCT images 
Three dimensional reconstructions of micro-computed tomography (µCT) scans (A,B) and radiographs (C,D) of 
mouse skulls after treatment to repair 5mm calvarial defects. The large bone formation in the µCT (A) is seen as a 
region of radio dense tissue in the corresponding radiograph (C). However, the trabecular nature of the regenerated 
bone indicated by µCT (A) is not conveyed by standard radiographic analysis (C). Normal size and shape of 
regenerated bone (B) with the corresponding radiograph (D). A radiographic comparison of the two samples would 
interpret sample C being better than sample D. However, with µCT analysis, sample B shows optimal bone 
formation. µCT allows for more accurate determination of the quality of the regenerated bone. 
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3.3.1.4 The future of “critical size defects” 
Since critical size defects were arbitrarily defined rather than experimentally generated, and 
researchers have found problems with the definition, we have three choices: 1) we can use the 
term “critical size defect” as defined by Schmitz et al. [224] and strengthen it by analyzing the 
healing of defects of all sizes at the end of the animals’ lifetimes to experimentally determine the 
smallest defect that will not heal in the lifetime of the animal; 2) we can re-define the CSD as 
any defect that does not heal over the duration of the study and have no standardization or good 
clinical correlate to the model; or 3) discontinue the use of the term “critical size defect.” 
Of these choices, the most logical is to discontinue the use of the term “critical size 
defect.” The model has only a limited clinical applicability and currently only serves to 
standardize the research methodology. However, through the use of µCT, we can more 
accurately define the size of our initial defect in live animals and more accurately measure the 
amount (volume) and quality (density) of formed bone. Such quantifiable measurements allow 
each researcher to design a surgical defect model that most closely resembles their area of 
clinical interest. Technology is enabling us to quantify small differences in the amount and 
quality of bone formation within small defects and more readily create useful animal models of 
human disease. The future of bone research will lie in the development of treatment modalities 
that are tailored to specific clinical applications. This strategy necessitates the use of appropriate 
animal models and technological advances and minimizes the need for a critical size defect 
model. 
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3.3.2 A New Model for Postoperative Resynostosis 
This chapter presents data that led to the development of a new model of postoperative 
resynostosis in an adult mouse. We needed to develop a model to allow us to test strategies to 
control bone growth and inhibit resynostosis after surgery to correct craniosynostosis. Because 
CSDs were defined as the smallest defect that would not heal, we were confident that any defect 
smaller than critical size would readily heal. The work presented here shows that simply making 
smaller defects is not sufficient to achieve reproducible healing. In fact, while we were testing 
defect sizes, Cowan et al. demonstrated (in their supplementary online data) that sub-critical size 
defects did not heal within 12 weeks after surgery [243]. We also found that surgical technique 
aimed to ensure the maintenance of the dura mater underlying the defect did not help small 
defects heal consistently up to 1 year postoperatively (Figure 12). Finally, we found that small 
defects made in a reputedly osteogenic (rat) parietal bone did not heal completely (Figure 13). 
Cowan et al. showed that very small, 0.8mm diameter, defects made in the parietal bones 
of mice were able to heal completely within 12 weeks after surgery [243]. Knowing that defects 
had to be that small, we sought to create a model that was more appropriate for our intended 
clinical use. We therefore used a small 0.5mm diameter cutting bur to perform a suturectomy on 
the posterior interfrontal suture that undergoes non-pathological synostosis early in the mouse 
life. Defects created in this way were shown to heal completely within 12 weeks of surgery. 
More importantly to our model, the interfrontal suture resynostosed as it healed. 
We believe that this model can be useful to test therapies targeted to inhibit the formation 
of bone within small calvarial defects. Furthermore, we believe that the use of µCT technology 
will strengthen the use of such models with respect to the non-uniformity of the initial defects. 
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4.0 THE EFFECTS OF NOGGIN GENE THERAPY ON POSTOPERATIVE 
RESYNOSTOSIS 
4.1 INTRODUCTION 
Craniosynostosis is the term given to the premature fusion of one or more of the cranial 
sutures [1] and it occurs with an estimated birth prevalence of 300-500 cases per 1,000,000 live 
births [2]. Craniosynostosis causes secondary deformation of the cranial vault, cranial base, and 
the midface often leading to increased intracranial pressure, and altered intracranial volume [15-
24]. Currently, the surgical intervention to correct craniosynostosis involves release of the 
synostosed suture, cranial vault decompression, and extensive craniofacial bone reconstruction 
[2-4, 28, 31-33, 38, 41-44]. Although such strategies have improved the long-term outcomes of 
surgical intervention, the suturectomy site often reossifies, causing increased intracranial 
pressure, restricting brain growth, and altering craniofacial growth [4, 5, 28, 38, 44-52, 54]. The 
detrimental effects of postoperative resynostosis necessitate secondary surgeries and increase 
patient morbidity and mortality [60, 61]. Because of the failures of current surgical interventions 
and the desire to avoid secondary surgeries, further work must be done to improve the outcomes 
for children presenting with craniosynostosis.  
The genetic mutations that lead to a handful of the syndromes involving craniosynostosis 
recently have been elucidated [40]. Unfortunately, the occurrence of syndromic craniosynostosis 
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only accounts for approximately 11% of all cases of craniosynostosis [2]. The vast majority of 
craniosynostosis cases are nonsyndromic and have no known genetic basis. Because of the 
unknown causes of nonsyndromic craniosynostosis, it surely will prove difficult to develop 
molecular therapies that can be tailored to specific individuals or specific cases.  
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor 
beta superfamily of proteins that were initially characterized by Urist in 1965 [145]. Several 
BMPs, including BMP2, BMP4, and BMP7 have been shown to be potent inducers of bone 
formation and are expressed during bone healing events [209, 244]. Noggin is an extracellular 
antagonist that binds directly to and inhibits the activity of BMP2, -4, and -7 [131, 132, 223]. 
Noggin has been shown to inhibit BMP induced bone formation in several different models [211-
213, 245]. Noggin’s ability to inhibit BMP-induced bone formation may be useful in inhibiting 
postoperative resynostosis. 
Previous studies have shown that Noggin protein therapy was capable of inhibiting bone 
formation and resynostosis in rabbits. However, the data also show that Noggin seemed to exert 
its effect in the first 15 days after implantation. One means of achieving longer-term exposure of 
the injury site to a therapeutic protein is through gene therapy. Gene therapy can be defined here 
as the genetic manipulation of cells to produce a desired effect. In this case, the desired effect is 
the production of exogenous Noggin protein. 
There are two strategies for the delivery of genetic material for therapeutic purposes. The 
direct application of vectors containing genetic material to the cells, tissues, or organs of interest 
within the living organism is termed in vivo, or direct, gene therapy. The use of in vivo gene 
therapy is hampered by the inability to control the type of cell that is infected by the vector being 
added. Any cell that comes into contact with the vector can potentially uptake the vector and 
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become altered. Also, it is extremely difficult to control the number of cells that are altered after 
the material is implanted in the body, making dosage difficult to control. The second strategy for 
gene-based therapies involves the implantation of genetically altered cells to deliver a protein of 
interest. This strategy is termed ex vivo gene therapy. Ex vivo approaches allow control of the 
cell type that will be altered and the number of altered cells that can be delivered to the injury 
site. For either in vivo or ex vivo approaches, it is important to choose the correct vector to 
introduce transgenes, the DNA that will cause the expression of the protein of interest. 
4.1.1 Gene Therapy Vectors 
4.1.1.1 cDNA plasmids 
Plasmids are safe vectors used for short-term transient transfection of cells. The drawback of 
plasmid vectors is the low transfection efficiency whereby only a small percentage (usually 
around 30%) of cells receives the transgene and produces functional protein. Also, when cells are 
successfully transfected, they will only express the exogenous protein for a few days (usually 3-5 
days). Recent reports using cDNA plasmids for bone regeneration attempt to increase the uptake 
of the plasmid by adding cationic liposomes [246] or poly(ethlenimine) (PEI) [247]. These 
authors chose to deliver the plasmid by hydroxyapatite scaffold [246] or by poly(lactic-co-
glycolic acid) (PLGA) scaffold [247]. The addition of plasmids to scaffolds that slowly degrade 
and release the plasmid is a promising direction for developing safe gene-based bone therapies. 
4.1.1.2 Adenoviral vectors 
Transduction of cells using adenoviral vectors leads to longer expression than plasmid 
transfection. Some recent reports have used luciferase activity to analyze expression patterns in 
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vivo and found that adenoviral vectors can cause expression of protein for anywhere from 10 
[176] to 14 days [180]. Many investigators have recently used adenoviral vectors to induce 
expression of BMPs or VEGF using either in vivo or ex vivo gene therapy techniques [173-180, 
248]. One drawback for the use of adenoviral vectors is that they usually cause a host immune 
response which deters their use in clinical applications. Another drawback is the fact that there is 
a loss of transgene expression when a transduced cell divides because the genetic material 
remains episomal and does not incorporate into the infected cell’s genome. 
4.1.1.3 Adeno-associated viral vectors 
Wild-type adeno-associated viruses (AAVs) are capable of incorporating into the host DNA, 
offering long term expression. However, a recent report by Gafni, et al., 2004, used luciferase to 
test the expression of an inducible AAV-2-based vector and found luciferase expression for only 
20 days after implantation [249]. Therefore, the use of recombinant AAV-based vectors does not 
guarantee DNA integration and long-term expression. AAV vectors, unlike adenoviruses, do not 
normally cause an immune response and are therefore of clinical interest. A recent report 
adhered AAV-based vectors for VEGF and RANKL to allografts to improve allograft bone 
remodeling [250]. Unlike wild-type vectors, genetic material delivered via recombinant AAVs 
does not incorporate into the transduced cell’s genome.  
4.1.1.4 Retroviral vectors 
The important characteristic of retroviral vectors is that transgenes get incorporated into the host 
cell’s DNA. This fact allows for long-term expression of the transgene throughout the life of the 
cell as well as its progeny. Retroviruses are less clinically applicable due to the inability to 
control the site of insertion of the transgene into the DNA. Transgene insertion into essential 
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regions of host DNA can lead to cancer or cell death. Retroviral vectors are therefore normally 
used in ex vivo gene therapies where the target cell (host) can be controlled and assessed for 
viability and tumorgenicity. Several recent reports, including some from our laboratory, have 
shown the effectiveness of retroviral-based gene therapies to induce or improve bone formation 
[179, 194, 251-253]. The long-term expression of the transgene with this vector necessitated the 
development of regulatable protein expression systems. Our laboratory reported on the 
development of a retroviral-based system that causes expression of the transgene only in the 
presence of Doxycycline [253]. Since then, we have used this vector encoding for BMP4 to 
improve the healing of calvarial defects in mice [245]. Retroviral vectors are good tools to study 
the interactions of proteins due to the long-term expression following transduction.  
4.1.2 Ex Vivo Gene Therapies using Different Cell Types 
The process of ex vivo gene therapy involves the genetic manipulation of cells in vitro before 
they are introduced into the site of desired effect. The cells used in this process must be able to 
express the transgene and, optimally, should be able to participate in tissue regeneration. Many 
investigators have identified cell sources from postnatal tissue that show potential for use in bone 
regeneration applications. 
4.1.2.1 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) can be isolated from bone marrow aspirate. These cells have 
been shown to be able to differentiate into bone [254] and can be used in ex vivo gene therapy 
approaches for bone regeneration [175, 179].  However, there are very few MSCs present within 
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bone marrow aspirate. This scarcity of cells necessitates long culture periods to increase the cell 
number to an applicable level. For this reason, the clinical application of MSCs is limited. 
4.1.2.2 Adipose-derived cells 
Recently, several groups have shown that cells derived from adult adipose tissue are capable of 
undergoing osteogenic differentiation [192, 193]. Recently, Peterson et al. (2005) showed the 
ability of human adipose-derived cells transduced with AdBMP2 to improve healing in long 
bone defects in nude rats [178]. Adipose-derived cells are of interest clinically because adipose 
tissue is abundant, easy to collect, and the cells are fairly easy to isolate. However, these adipose-
derived cells are a heterogeneous population of cells. Therefore, it is still unclear which cells 
within the population are directly responsible for bone formation.  
4.1.2.3 Skeletal muscle-derived cells 
In 2000, our laboratory reported on the use of populations of cells, derived from the muscles of 
postnatal mice, to enhance bone regeneration [198]. Since then, we have utilized retroviral-
mediated gene transfer of BMP2 and BMP4 to enhance bone regeneration within cranial and 
long bone defects in mice and rats through ex vivo gene therapy [251-253, 255, 256]. We also 
have combined BMP4 and VEGF gene-based therapies to further enhance bone formation [256].  
4.1.3 Gene Therapy for Postoperative Resynostosis 
In order to test the effects of Noggin on the inhibition of postoperative resynostosis, a treatment 
strategy was developed to have long-term Noggin exposure at the suturectomy site. A novel 
retroviral vector was developed using previously established backbones [253] that induced the 
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expression of both Noggin and green fluorescent protein (GFP) in the infected cell. A retroviral 
vector was chosen because of its ability to incorporate the transgene into the host cell’s genome, 
allowing for longer-term expression of Noggin. Muscle-derived stem cells were chosen because 
these cells have been shown to have the ability to survive implantation and express transgenes 
for an extended period of time [199, 245, 251-253, 255-258]. An ex-vivo approach was used in 
this study to control the cell type that was transduced and to allow for controlled dosage by 
standardizing the number of cells that were implanted in the surgery site. 
4.2 HYPOTHESIS 
This study was designed to test the hypothesis that ex vivo Noggin gene therapy would inhibit 
bone formation and resynostosis in a mouse model of postoperative resynostosis. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Cell Culture 
Muscle-derived stem cells (MDSCs) were isolated from the skeletal muscle of postnatal mice as 
described previously [198, 259]. Cells were cultured in proliferation medium (DMEM 
supplemented with 10% fetal bovine serum (FBS, Invitrogen), 10% horse serum (HS, 
Invitrogen), 1% penicillin/streptomycin (Invitrogen), and 1% chick embryo extract (CEE, 
Accurate Chemical and Scientific Corporation, Westbury, NY) on collagen-coated flasks 
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(Collagen I, Sigma) as described previously [259]. Cells were grown until a sufficient number 
was reached to use for transduction. 
4.3.2 Cell Transduction 
Cells were plated at low confluence into an uncoated T25 flask and allowed to attach in 
proliferation medium. The next day, cells were transduced with a 1:1 ratio of either a retroviral 
vector to express GFP (CLGFP) or Noggin and GFP (CLNogG) to proliferation medium along 
with 8µg/ml Polybrene. The retroviral vector construction was described previously [253] 
(Figure 18A) with either of two alterations (Figure 18B,C). The cells were transduced for 3 
days with 3 changes of the medium containing the retrovirus. Cells were then split and plated 
into T75 flask and grown for cryo-storage and bioassay. After 2 days in culture, cells were 
inspected with fluorescence microscopy to estimate transduction efficiency. 
 
 
Figure 18: Structures of retroviral vectors 
Diagram showing the structures of the retroviral vectors used in this study. A) The original retroviral vector, as 
described in Peng et al., 2004 [253] which included a BMP2/4 gene and a gene encoding enhanced green fluorescent 
protein (EGFP) preceded by an internal ribosome entry site (IRES) allowing for coincident expression of both BMP 
and GFP genes. B) Novel retroviral vector created by cutting out the BMP2/4 gene in A and replacing it with the 
Noggin gene (as developed in Peng et al., 2005 [245]). C) Retroviral vector encoding only the GFP gene. 
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4.3.3 Bioassay 
In order to test the expression of functional Noggin in our transduced cells, we performed a 
bioassay as previously described [212, 245]. Briefly, cells were seeded in 6 well plates and 
allowed to grow to confluence in proliferation medium. After reaching confluence, the medium 
was changed and the cells grew for an additional 48 hours. At this time, the conditioned medium 
(CM) was collected and the cells were counted using a Trypan Blue exclusion assay. Functional 
Noggin expression was quantified using Noggin’s ability to inhibit BMP4’s induction of alkaline 
phosphatase (ALP) activity in C2C12 cells. C2C12 cells are a myogenic cell line that is 
responsive to BMP4 signaling by becoming ALP-positive. Control cells were stimulated with 
either BMP4 only (50ng/ml), with BMP4 and a known dilution of Noggin, or with proliferation 
medium only. Serial 2-fold dilutions of CM were added to C2C12 cells at the same time as 
50ng/ml of BMP4. The amount of Noggin within each sample can be quantified by determining 
the number of dilutions that it takes before the CM is unable to inhibit BMP4 activity (cells turn 
blue after ALP staining).  
4.3.4 Scaffold Seeding 
Cells were seeded onto compressed Gelfoam® scaffolds as previously described [245, 253, 255, 
256]. Briefly, the day before surgery, cells were trypsinized and counted. Two millimeter thick 
compressed Gelfoam® was cut into 3x3mm squares (yielding 3x3x2mm scaffolds) under sterile 
conditions and each scaffold was placed into a well in a 6 well plate. Cells were resuspended in 
proliferation medium to a concentration of 4x105cells/25µl. Each 25µl aliquot was added to a 
Gelfoam® scaffold and allowed to soak into the scaffold (approximately 20 minutes). After the 
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cells had penetrated into the scaffold, 3ml of medium was added to each well and the construct 
was allowed to incubate overnight at 37°C. The next day, only constructs that showed very few 
cells attached to the well or in the medium were used for implantation.  
4.3.5 Sample 
One hundred-eight male C57BL/6J mice, 10 weeks old, were used in this study. The mice were 
randomly assigned to three groups as follows: Group 1) Suturectomy with no treatment, which 
served as the surgical control group (n = 36); Group 2) Suturectomy treated with cells expressing 
green fluorescent protein (GFP) in Gelfoam®, which served as the cell and vehicle control group 
(n = 36); and Group 3) Suturectomy treated with cells expressing Noggin and GFP in Gelfoam®, 
which served as the treatment group (n=36). 
4.3.6 Surgical Technique 
As seen in the data presented in Chapter 3 of this work, we have developed a novel model for 
postoperative resynostosis in the adult mouse. At 10 weeks of age, all mice were anesthetized 
with 4% isofluorane via inhalation. Anesthesia was maintained using 2% isofluorane via a 
nosecone. The scalps were shaved and prepared for surgery. Under sterile conditions, the 
calvaria were exposed via a midline scalp incision, and the skin was reflected laterally to expose 
the midline sutures. The fused interfrontal sutures were identified and the overlying periosteum 
was removed. A 0.5mm cutting burr fixed to a hand engine (2000rpm) was used to remove a 
region of the posterior interfrontal suture approximately 1mm in anteroposterior length, for a 
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final defect approximately 0.5mm x 1.0mm in size. Care was taken to avoid damage to the 
underlying dura mater and sagittal sinus.  
In mice in the suturectomy control group (Group 1), the suturectomy was performed with 
no further treatment and the skin was reapproximated and closed using with 4-0 silk suture. In 
mice in the cell/vehicle control group (Group 2), a Gelfoam® scaffold loaded with 4x105 GFP-
expressing cells was used to cover the suturectomy site. In mice in the experimental group 
(Group 3), the suturectomy site was covered with a Gelfoam® scaffold loaded with 4x105 cells 
expressing Noggin and GFP. In mice in Groups 2 and 3, the skin was reapproximated along the 
midline to cover the implant and the skin was closed using 4-0 silk suture. Animals from each 
group were killed 4, 8, and 12 weeks after surgery, heads were removed, and skulls were fixed in 
10% neutral buffered formalin for 24 hrs. Following fixation, skulls were removed from fixative 
and placed in 70% ethanol for storage. 
4.3.7 Radiographic Analysis 
Each sample was processed for radiographic analysis the same way. The cranial base and brain 
were removed prior to scanning. Radiographs were taken at 5x magnification with a Faxitron 
(MX-20, Faxitron X-ray Corporation) set to 35kV and 250sec exposure on Kodak X-OMAT V 
film. Developed x-ray films were scanned with a Microtek ScanMaker 9800XL set for 
radiographic scanning at 1200dpi. The images generated were then imported into Northern 
Eclipse software (Empix Imaging) for digital measurement of defect area. 
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4.3.8 µCT 
The animals in each group that were to be killed at the 12 week time point were serially scanned 
on a VivaCT40 scanner (Scanco Medical, USA) 4, 8, and 12 weeks after surgery (55kVp, 
142µA, scan length: 3.12mm, scan time: 5 minutes, voxel size: 30µm). Each scan produced 104 
images (Figure 19A) that encompassed the entire region of interest. On each image where there 
was a visible defect, the margins of the defect were traced (Figure 19B) and the total defect 
volume was calculated using the VivaCT software. 
 
 
Figure 19: 2D µCT scan of live mouse with defect 
A) Photograph showing a single 2-dimensional slice that is used to measure defect volume. B) Image showing a 
representative tracing of the margin of the defect in the slice shown in A. Each scan for this study generated 104 
such images that were used to generate the 3-dimensional reconstructions. 
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4.3.9 Histology 
Samples were decalcified in 10% EDTA for 7 days, dehydrated in serial alcohols, and processed 
for paraffin embedding. Paraffin blocks were cut on a microtome at 5µm thickness every 75µm 
 frontonasal suture, through the frontal bones, to the bregma. Slides 
were stained with hematoxylin and eosin for qualitative histological analysis. 
Means and standard deviations for 2-dimensional defect areas were calculated and compared 
differences were assessed using the LSD multiple comparisons test (SPSS v12.0.1). Means and 
standard deviations for 3-dimensional defect volumes were calculated and compared among 
 4 (surgical group by time) multiple comparisons test to assess group and 
age interactions. One way analysis of variance was performed to assess group differences at each 
time point (3 x 1 surgical group by time). Mean differences were considered significantly 
ifferent if p < 0.05.  
 
 
in the coronal plane from the
4.3.10 Statistical Analysis 
among conditions using a 3 x 1 (surgical group by time) one way analysis of variance. Intergroup 
conditions using a 3 x
d
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4.4 RESULTS 
4.4.1 Noggin Expression 
Qualitative microscopic analysis showed viable cells following transduction (Figure 20A). We 
found variable levels of GFP expression among cells within the population, but greater than 90% 
transduction efficiency (Figure 20B).  
 
 
Figure 20: Photomicrographs showing transduction efficiency 
A) Phase contrast image of MDSCs transduced with the CLNogG retroviral vector. B) Fluorescent image of the 
same field as A showing expression of GFP after transduction with CLNogG retroviral vector. Note that there was 
nearly 100% transduction efficiency after the three day exposure to retroviral vector. 
 
Cell counts for the CM samples used for the bioassay showed that, in a confluent well of a 6 well 
plate, there were approximately 5x106 cells. By testing the CM collected from these confluent 
wells, we found that the CM from a single well had approximately 125ng/ml of Noggin (Figure 
21). Adjusting for cell number, media volume, and collection time, we determined that these 
cells produced approximately 35.4ng/106cells/day. 
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Figure 21: Noggin concentration as determined by bioasay 
Photograph of lanes of 96 well plate seeded with C2C12 cells. All cells were fed with 50 µl of 50ng/ml BMP4 and 
50µl of dilutions of either known amounts of Noggin (NOG, left lane, known concentration shown) or conditioned 
medium (CM, right lane). Noggin control becomes too dilute to inhibit BMP4 activity at 3.9ng/ml. The CM lane is 
considered 3.9ng/ml in the first well that turns blue. By doubling the concentration for each well above the first blue 
well, the initial concentration of the CM is determined. 
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4.4.2 Radiographic Analysis 
Radiographs showed that defects in all groups healed over time (Figure 22). The Noggin treated 
defects grossly seemed to be larger than either GFP or control defects at 4 and 8 week time 
points. 
 
 
 
Figure 22: Radiographs of healing interfrontal defects 
Radiographs taken from animals killed 4, 8, or 12 weeks after interfrontal suturectomy. Notice that the Noggin 
treated defects tend to be larger than the GFP treated or untreated control defects. 
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Statistical analysis of defect areas measured from radiographs revealed significant group 
(F=5.56;p<0.01) and age (F=9.40;p<0.001) main effects. A significant group x age interaction 
effect was noted (F=2.95;p<0.05), showing that defect area was changing differently among 
groups over time. Four weeks after surgery, there was a significant difference between the areas 
of untreated control defects (0.0929mm2 ± 0.06) compared to defects treated with Noggin 
expressing cells (0.1808mm2 ± 0.09; p<0.05). The GFP treated defects (0.1379mm2 ± 0.08) were 
not significantly different from either untreated control or Noggin treated defects (Figure 23A). 
At 8 weeks after surgery, the Noggin treated defects (0.1476mm2 ± 0.09) were significantly 
larger than either untreated control defects (0.0755mm2 ± 0.04) or GFP treated defects 
(0.0699mm2 ± 0.03; p<0.01; Figure 23B). 12 week data show no significant differences between 
any of the treatment groups (Figure 23C). 
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Figure 23: Defect areas 4, 8, and 12 weeks after surgery 
A) Graph of the radiographic data of the 2D defect areas (±SEM) of defects from the three surgical groups 4 weeks 
after surgery. At this time, the Noggin treated defects (Nog-GFP) were statistically larger than control untreated 
defects. B) Graph of defect areas (±SEM) 8 weeks after surgery showing that Noggin treated defects were 
significantly larger than both untreated control and GFP treated defects. C) Graph of defect areas (±SEM) 12 weeks 
after surgery showing no differences in the mean areas between the treatment groups. 
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4.4.3 µCT Analysis 
Longitudinal 3D µCT reconstructions showed that all defects in all groups healed over time 
(Figure 24). One animal in the control, untreated group showed evidence of an infection when it 
was killed 12 weeks postoperatively and all postoperative measurements from this animal were 
excluded from the study. No animals in any group showed complete healing of the interfrontal 
suturectomy over course of the study. 
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Figure 24: 3D µCT reconstructions showing longitudinal defect healing in live animals 
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Two-way ANOVA (3 x 4 group by time) on defect volumes measured from µCT scans 
revealed significant group (F=20.85;p<0.001) and age (F=143.950;p<0.001) main effects (Table 
1). A significant group x age interaction effect was noted (F=3.15;p<0.01), showing that defect 
volumes were changing differently among groups over time.  
Table 1. Sources of Variability for 3 x 4 2-way ANOVA (Day 0, 4, 8, and 12 Weeks Postoperatively) 
Sources of Variability Sum of Squares Mean Square F Sig. 
Group .045 .023 20.850 .000 
Time .468 .156 143.950 .000 
Group x Time .020 .003 3.149 .007 
Error .139 .001   
 
Immediately postoperatively (Day 0), there was no significant volume differences among 
the treatment groups (Table 2, Figure 25, F=0.029;NS). Four weeks after surgery, there were 
significant differences between the volumes of all groups (Table 2, Figure 25, 
F=14.73;p<0.001). Eight weeks after surgery, volumes of Noggin and GFP treated defects were 
significantly larger than control defect volumes (p<0.05), but not different between Noggin and 
GFP treated defects (Table 2, Figure 25). By 12 weeks after surgery, Noggin treated defects 
were significantly larger than either GFP or untreated control defects (p<0.01) while GFP and 
control defects were not significantly different (Table 2, Figure 25). 
Table 2. Means and Standard Deviations of Defect Volumes 
Group Day 0 
Mean Volume 
±SD (mm3) 
4wk 
Mean Volume 
±SD (mm3) 
8wk 
Mean Volume 
±SD (mm3) 
12wk 
Mean Volume 
±SD (mm3) 
Control (n=11) .1970 ± .0388 .0469 ± .0220 .0425 ± .0216 .0287 ± .0200 
GFP (n=12) .2009 ± .0468 .0949 ± .0295‡ .0709 ± .0275‡ .0460 ± .0178 
NOG (n=12) .1980 ± .0367 .1307 ± .0519*† .0893 ± .0296* .0744 ± .0307*† 
*=Nog vs. control, †=Nog vs. GFP, ‡=GFP vs. control 
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Figure 25: Defect volumes over time 
Graph showing defect volume changes (±SEM) measured from longitudinal µCT scans at different postoperative 
time points (see Table 2). All groups healed over time. Noggin treated defects were significantly larger than control 
defects at all time points after surgery (*). Noggin treated defects were significantly larger than GFP treated defects 
4 and 12 weeks after surgery (†). GFP treated defects were significantly larger than control defects both 4 and 8 
weeks after surgery (‡). 
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Over the first 4 weeks of the study, the untreated control group showed significant 
healing (approximately 76% of the original defect size). Between 4 and 12 weeks 
postoperatively, these defects only healed an additional 9% of the original defect size (for a total 
of approximately 85% healing). Because of this difference in healing rates, the data seemed to 
show two distinct phases of defect healing. The first phase was characterized by rapid healing of 
the defects and occurred within the first 4 weeks following surgery. The second phase was 
characterized by small, incremental healing of the defect volume and occurred between 4 and 12 
weeks after surgery. A 3 x 2 (surgical group by age) 2-way ANOVA to compare changes in 
defect volume between day 0 and 4 weeks postoperatively among the treatment groups showed 
significant group and age main effects (Table 3). There was also a significant group x age effect 
(Table 3). Among 4, 8, and 12 week measurements, there were significant group and age main 
effects, but there was no group x age effect noted (Table 4).  
Table 3. Sources of Variability for 3 x 2 2way ANOVA (Day 0 and 4 Weeks Postoperativley) 
Sources of Variability Sum of Squares Mean Square F Sig. 
Group .021 .010 6.820 .002 
Time .203 .203 132.449 .000 
Group x Time .020 .010 6.433 .003 
Error .098 .002   
 
Table 4. Sources of Variability for 3 x 3 2way ANOVA (4, 8, and 12 Weeks Postoperativley) 
Sources of Variability Sum of Squares Mean Square F Sig. 
Group .059 .030 33.771 .000 
Time .030 .015 16.885 .000 
Group x Time .006 .002 1.714 .153 
Error .085 .001   
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4.4.4 Histological Analysis 
Qualitative analysis of cross sectional histological slides from animals killed 4, 8, and 12 weeks 
after surgery showed healing in all bone defects in all groups (Figure 26). The bony tissue 
within the defect was disorganized 4 weeks after surgery, and progressively became more 
organized. Sections were identified within each sample that showed remaining defects filled with 
fibrous tissue at each time point after surgery (Figure 26). 
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 Figure 26: Histology of suturectomy site healing 
Histophotomicrographs of interfrontal suturectomy sites from untreated (control), GFP treated (GFP), or Noggin 
treated (NOG) animals. Notice that defects in all groups showed healing within the defect.  
 
 81 
4.5 DISCUSSION 
Craniosynostosis is the term given to the premature fusion of cranial sutures. Such early suture 
fusion inhibits the normal growth of the brain, causes increased intracranial pressure, and 
necessitates surgical intervention. Although the surgical techniques currently employed normally 
lead to increased intracranial volume, decreased intracranial pressure, and improved craniofacial 
growth, the occurrence of resynostosis of the suturectomy sites can negatively affect 
postoperative outcomes. 
We believe that a molecular adjunct to surgical intervention that targets potent bone 
forming growth factors expressed during normal bone healing would function to inhibit bone 
formation and improve postoperative outcomes. 
This study was designed to test the hypothesis that postoperative treatment of a 
suturectomy site with Noggin, a BMP antagonist, would inhibit bone formation within the 
suturectomy site. 
To test this hypothesis, we used an ex vivo gene therapy approach to transduce muscle-
derived stem cells to constitutively express Noggin. These cells were implanted onto a mouse 
interfrontal suturectomy site within a gelatin scaffold. Defect healing was assessed using 
radiographic, µCT, and histological analyses. 
Radiographic analysis showed that Noggin treated defects were significantly larger than 
untreated control defects 4 and 8 weeks postoperatively. The difference observed at these earlier 
time points were not apparent 12 weeks after surgery. The GFP treated defects tended to be 
larger than the untreated control defects 4 weeks after surgery, but this difference diminished by 
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8 weeks after surgery. Although we expected the GFP treated defects to heal similarly to the 
untreated control defects, we assume that the inhibition that was observed in the GFP group 
came from some immune response that the mice had to the implantation of cells within a gelatin 
scaffold. In spite of this response that we assume was also present in the Noggin treated groups, 
the data suggest that only through the addition of Noggin was bone formation significantly 
inhibited. Twelve weeks after surgery, all of the defects were relatively the same size in all 
groups. From this radiographic data, we would conclude that ex vivo Noggin gene therapy 
inhibited bone formation for approximately 8 weeks in this model. 
Through the use of µCT technology, we were able to assess longitudinal defect healing in 
a cohort of these animals. Noggin treated defects were significantly larger than untreated control 
defects at all times after surgery. The GFP treated group healed differently than the untreated 
control group, evidenced by the statistically larger defects both 4 and 8 weeks after surgery. 
Finally, Noggin treated defects were significantly larger than the GFP treated defects 4 and 12 
weeks after surgery. These data show that both Noggin and GFP treatment significantly inhibited 
bone formation in this model 4 and 8 weeks after surgery. However, Noggin was more effective 
than GFP 4 weeks after surgery and was the only treatment group significantly larger than 
untreated controls 12 weeks after surgery. These data suggest that treatment of small 
suturectomy sites with transduced cells in a gelatin matrix can inhibit bone formation, but 
significant longer-term inhibition is only achieved when these cells express Noggin. Therefore, 
we feel confident that Noggin is effective in inhibiting bone formation in this model of 
resynostosis. 
The longitudinal µCT data also demonstrated a biphasic healing process that occurs in 
this model of resynostosis. The first phase of rapid healing occured within the first 4 weeks after 
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surgery. The second phase of slower healing occurred between 4 and 12 weeks. When we 
compared the defect volumes of the groups based on these phases, we found that Noggin 
treatment changed the rate of healing in the first phase, and had no effect on healing rate in the 
second phase, suggesting that the Noggin ex vivo gene therapy approach employed in this study 
did not have inhibitory effects after 4 weeks postoperatively. However, even though there was no 
evidence that our Noggin therapy continued to inhibit bone formation after 4 weeks, it did have a 
lasting effect on total bone formation, evidenced by the significantly larger defects in the Noggin 
treated group at 12 weeks.  
Furthermore, the fact that there was very little defect healing observed after 4 weeks in 
this model gives insight into the discrepancy between the µCT data and the cross-sectional 
radiographic data. First, because the radiographic data was collected 4, 8, and 12 weeks after 
surgery, it only represents the healing that occurred in the second phase of defect healing, not 
during the first, rapid phase. The µCT data showed that Noggin treatment had its effect during 
the first phase, not the second phase, making the radiographic data less indicative of Noggin’s 
possible effects. Second, the radiographic data is cross-sectional data, which means that the 
animals measured at 4 weeks postoperatively are not the same as the animals measured at either 
8 or 12 weeks postoperatively. This discrepancy is most evident in the fact that the mean defect 
area of the untreated control group 12 weeks after surgery was actually larger than the 8 week 
measurement. The µCT data show continuous healing in all groups over time, which is a more 
realistic healing pattern. Finally, the radiographic data is less indicative of the true defect size 
because it changes 3-dimensional data (volume) into 2-dimensional data (area). Radiographs 
allow for the measurement of the area in which there is no bone on either the ectocortical or 
endocortical surface. The µCT scans were able to show the true defect margins, whether or not 
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the defect spanned both cortices (see Figure 19). For example, if a defect is cone-chaped, larger 
on the ectocortical surface and only slightly pierces the endocortex, then the radiograph would 
show a defect that was the size of the small endocortical defect. Therefore, we feel that 
traditional radiographic data, at least in this model, is much less reliable than the µCT data. 
Though the causes of craniosynostosis are poorly understood, there is one trait that all 
cases, both syndromic and nonsyndromic, have in common: the overproduction of bone. In all 
cases, bone forms within the suture, a tissue that is supposed to be devoid of bone until the brain 
is completely grown. Regardless of the genetic or environmental etiology of the primary 
craniosynostosis, there is a risk of postoperative resynostosis [38, 52]. We believe that BMP 
signaling is at least in part responsible for calvarial bone healing and resynostosis following 
surgery. In fact, BMPs have been shown to be expressed in healing bone defects in the 
craniofacial skeleton [209].  
Noggin has previously been shown to antagonize ectopic bone formation induced by 
BMPs [211, 212]. A single study has shown evidence that Noggin can inhibit membranous 
ossification [213]. That study used a bone chamber technique which involves injury to the rat 
tibia and analyzed the amount of bone that formed within a chamber attached to the injury site 
[213]. The current study is the first to give evidence that Noggin can inhibit bone healing in 
normally healing calvarial bone defects. The results presented here suggest that using Noggin to 
inhibit BMP signaling was effective in the inhibition of postoperative resynostosis in this mouse 
model. We believe that using Noggin treatment as an adjunct to surgical intervention may be 
useful to inhibit resynostosis, regardless of the etiology that caused the primary craniosynostosis.   
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This study is the first to use µCT to analyze the healing of small suturectomy sites in 
living mice. It is also the first study that addresses the inhibition of postoperative resynostosis 
using molecular therapies in a mouse model.  
This model and similar analytical techniques can be used for continued research to inhibit 
postoperative resynostosis. 
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5.0 NOGGIN’S EFFECT ON BMP4-INDUCED BONE REGENERATION 
5.1 INTRODUCTION 
Bone is a notoriously regenerative tissue. Normally, in cases of fracture and surgical bone 
removal, bone has the capacity to heal itself. In many cases, however, bone defects heal with 
fibrous tissue, rather than with bone, termed a nonunion. Treatment of nonunions usually 
involves the surgical implantation of a bone graft to enhance healing. A recent review estimates 
that approximately 1.5 million bone grafting operations are performed each year [138]. 
Currently, autografting bone from other sites in the patient’s body is the gold standard for the 
treatment of nonunions. Though this technique usually results in healing of nonunions, donor site 
morbidity, the lack of available harvest sites (especially in the pediatric population), and the high 
risk of poor outcomes makes autografting suboptimal [139, 140]. 
 Many researchers have chosen to improve bone healing using potent bone-inducing 
proteins, the bone morphogenetic proteins (BMPs) -2, -4, and -7 [138, 149-151, 159-161, 260]. 
Although the results in animal experiments are overwhelming, the clinical use of BMPs has only 
recently begun [138]. It seems obvious that the clinical use of BMPs to assist the healing of 
many different type of defects will soon be a standard in clinical care.  
To understand the applicability of growth factor-based bone enhancement therapies, we 
must first understand the role of growth factors during normal bone healing. Growth factors and 
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their antagonists act concurrently during most physiologic processes ranging from normal 
development and growth to repair or regeneration of damaged tissues. For example, during 
vertebrate embryogenesis, BMP4 interacts with its antagonist, Noggin, during various inductive 
events [261]. Such interactions are responsible for the dynamic patterning of Noggin expression 
in somites [262]. BMPs also have been shown to induce the expression of Noggin in cultured 
osteoblasts [263]. In vivo studies have revealed coordinated expression of BMPs and Noggin 
during early skeletogenesis [264] and fracture healing [210]. Tissue engineering and regenerative 
medicine together constitute a new medical frontier based on the use of interdisciplinary 
approaches to enhance tissue repair, regeneration, or replacement. Stem cell-based therapy alone 
or in combination with genetic engineering or gene therapy has become an attractive tissue 
engineering approach. Indeed, studies have shown that a number of osteogenic BMPs, 
administered in the form of either proteins or genes, can enhance bone healing and improve bone 
regeneration [198, 245, 253, 256, 258, 260, 265-267]. 
Because few efforts have been made to imitate the natural healing process during which 
the expression of growth factors is accompanied by the expression of their specific antagonists 
[210], many current therapeutic strategies lead to less than optimal outcomes. There is a paucity 
of information regarding strategies to control the size and shape of regenerated bone. Especially 
in the craniofacial region, the size and shape of the reconstructed/regenerated bone must be 
controlled to maximize function and minimize any interference with surrounding structures (such 
as nerves, blood vessels, or sensory organs). Toward this aim, researchers recently have 
developed an inducible gene therapy vector that enables regulated expression of BMP2 or BMP4 
[267]. Our studies have demonstrated that MDSCs transduced by a tet-on self-inactivating 
retroviral vector expressing BMP4 and subcutaneously implanted elicit bone formation only in 
 88 
the presence of doxycycline (Dox) [253]. We also have reported that these transduced MDSCs 
can promote regulated bone regeneration in a critical-sized skull defect [245]. Additionally, we 
have tested the hypothesis that administration of the specific BMP4 antagonist Noggin can 
further control the bone regeneration induced by stem cells expressing inducible BMP4 [245]. 
Our results show that the simultaneous administration of Noggin and BMP4 at a ratio of 1:5 
(Noggin-expressing cells:BMP4-expressing cells) elicits the physiologic response that occurs 
naturally during fracture healing [245]. The simultaneous expression of these factors provided us 
with more stringent control over the inducible therapeutic effects of BMP4, and facilitated the 
regeneration of bone that more closely resembled the original tissue [245].  
5.2 HYPOTHESIS 
We hypothesized that a high ratio of Noggin expressing cells to BMP4 expressing cells will 
result in the formation of less ectopic bone and more dense bone within the defect site. 
5.3 MATERIALS AND METHODS 
5.3.1 Cell Culture 
Muscle-derived stem cells (MDSCs) were isolated from the skeletal muscle of postnatal mice as 
described previously [198, 259]. MDSCs were cultured in proliferation medium (DMEM 
supplemented with 10% FBS [Invitrogen], 10% HS [Invitrogen], 1% penicillin/streptomycin 
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[Invitrogen], and 1% chick embryo extract [CEE, Accurate Chemical and Scientific Corporation, 
Westbury, NY]) on collagen-coated flasks (Collagen I, Sigma) as described previously [259]. 
Cells were grown until a sufficient number was reached to use for transduction. 
5.3.2 Cell Transduction 
Three populations of MDSCs were developed in this study from a single population of cells 
derived from postnatal muscle of C57BL/6J mice. The first population was transduced to express 
both BMP4 and β-galactosidase (B4 cells) using previously described vectors and protocols 
[256, 260, 268]. The second population of the same parent MDSCs was transduced to express 
Noggin and GFP (NOG cells) as described above (Section 4.2.2). The third population of 
MDSCs was transduced to express β-galactosidase only, to serve as a control transduced MDSC 
population (control). After transduction, proliferation of NOG cells was tested by plating 1x104 
cells per well in a 6-well plate and cells were counted using a Trypan Blue exclusion assay 48 
hours after seeding. Cell numbers were compared to untransduced (naïve) cells cultured the same 
way. 
5.3.3 Scaffold Seeding 
Cells were seeded onto compressed Gelfoam® scaffolds as previously described [245, 253, 255, 
256]. Briefly, the day before surgery, cells were trypsinized and counted. Two millimeter thick 
compressed Gelfoam® was cut into 5x5mm squares (yielding 5x5x2mm scaffolds) under sterile 
conditions and each scaffold was placed into a well in a 6 well plate. All three populations of 
MDSCs were resuspended in proliferation medium. Cells were mixed together at the correct 
ratios (Table 5), centrifuged, and resuspended to a concentration of 1.5x105cells/25µl. Each 25µl 
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aliquot was added to a Gelfoam® scaffold and allowed to soak into the scaffold (approximately 
20 minutes). After the cells had penetrated into the scaffold, 3ml of medium was added to each 
well and the construct was allowed to incubate overnight at 37°C. The next day, only constructs 
that showed very few cells attached to the well or in the medium were used for implantation. 
Extra cell aliquots were seeded directly onto 6-well plates for imaging 24 hours later. 
 
Table 5. Cell Number for Each Group of Constructs 
 # of B4 cells # of NOG cells # of control cells 
GROUP 1 
1:2 control:B4 cells 
1 X 105 0 5 X 104
GROUP 2 
1:2 NOG:B4 cells 
1 X 105 5 X 104 0 
GROUP 3 
1:5 NOG:B4 cells 
1 X 105 2 X 104 3 X 104
GROUP 4 
1:10 NOG:B4 cells 
1 X 105 1 X 104 4 X 104
GROUP 5 
1:20 NOG:B4 cells 
1 X 105 5 X 103 4.5 X 104
 
5.3.4 Sample 
Twenty-two, 10 week old, male C57BL/6J mice (Jackson) were randomly assigned to five 
groups: Group 1) Defects treated with control and BMP4 expressing cells at a 1:2 ratio served as 
a BMP4 control group (n = 5); Group 2) Defects treated with Noggin and BMP4 expressing 
cells at a 1:2 ratio served as the highest concentration of Noggin expressing cells (n = 5); Group 
3) Defects treated with Noggin and BMP4 expressing cells at a 1:5 ratio (n=4); Group 4) 
Defects treated with Noggin and BMP4 expressing cells at a 1:10 ratio (n=5); and Group 5) 
Defects treated with Noggin and BMP4 expressing cells at a 1:20 ratio (n=3) served as the lowest 
concentration of Noggin expressing cells. All animals were killed 6 weeks after surgery. This 
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protocol was approved by the Animal Research and Care Committee at Children’s Hospital of 
Pittsburgh. 
5.3.5 Surgical Technique 
In each animal in each group, calvarial defects were created along the midline using a 5mm outer 
diameter round trephine (Fine Science Tools) as previously described [245]. In all animals, the 
cell/scaffold constructs were placed within the defects and the skin was approximated to cover 
the construct and sutured together. 
5.3.6 µCT 
Animals in each group were scanned on a VivaCT40 scanner (Scanco Medical, USA) 3 and 6 
weeks after surgery (55kVp, 142µA, scan length: 6.36mm, scan time: 10 minutes, voxel size: 
30µm). Each scan produced 212 images encompassing the entire 5mm bone defect region. On 
each image where there was a visible defect, a region of interest (ROI) was defined (Figure 27A, 
region #1) and the bone volume and bone volume mean density within the defect was calculated 
using the VivaCT software with a threshold set at 192. Mean densities were determined by 
calibrating the VivaCT using a phantom that has samples of known concentrations of 
hydroxyapatite (HA). Therefore, mean density was measured in terms of milligrams of HA per 
cubic centimeter (mgHA/cc). Following these calculations, the images were reopened and the 
defect ROI was used to define a region above and a region below the defect (Figure 27B, region 
#2). Then, the original defect ROI was deleted to leave only the ectopic bone ROI (Figure 27C, 
region #2). The ectopic bone volume and mean density was determined from this ROI in each 
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scan. Finally, the defect bone volume and ectopic bone volumes were added together to 
determine total bone volume and an efficiency measurement was calculated by dividing defect 
bone volume by total bone volume.  
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 Figure 27: µCT measurement technique 
A) Two-dimensional µCT scan showing the delineation of the defect region of interest (ROI) outlined in yellow 
(#1). B) Scan showing how the defect ROI (#1) was used to define the ectopic ROI (#2). C) Scan showing the 
ectopic ROI (#2) after the defect ROI was removed. ROI #1 was used to measure defect bone volume and defect 
bone volume mean density. ROI #2 was used to measure ectopic bone volume and ectopic bone volume mean 
density. 
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5.3.7 Statistical Analysis 
Means and standard deviations for defect bone volume (DBV), defect bone volume mean density 
(DBVMD), ectopic bone volume (EBV), ectopic bone volume mean density (EBVMD), total 
bone volume (TBV), and treatment efficiency (DBV/TBV) were calculated and compared among 
groups at each time point using one way analysis of variance (ANOVA). Significant intergroup 
differences at each age were assessed using the Least Significant Differences multiple 
comparison test. The relationship between bone volume and bone density, or bone volume and 
efficiency was also assessed using Pearson product moment correlations. All data were analyzed 
using SPSS 12.0 for windows (SPSS, Inc., Chicago, IL). Differences were considered significant 
if p < 0.05. 
5.4 RESULTS 
5.4.1 Cell Culture 
All cell populations survived transduction. A comparison of cell numbers showed no significant 
difference between the number of NOG cells (6.67x104 ± 2x104) compared to untransduced cells 
(8.33x104 ± 6x103) after 48 hours of culture (p=0.252,NS). 
5.4.2 Scaffold Seeding 
After cell aliquots were seeded onto the gelatin scaffolds, extra aliquots were plated into 6-well 
plates. NOG cells were transduced to simultaneously express both Noggin and GFP while the B4 
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cells expressed β-galactosidase. Photographs of an extra aliquot from Group 2 (1:2 NOG:B4; 
Figure 28A) showed the presence of a population of GFP-positive NOG cells (Figure 28B) 
within the majority of the cells that were not expressing GFP (Figure 28C). 
 
 
Figure 28: Micrographs of 1:2 NOG:B4 cell mixture 
A) Phase contrast micrograph showing mixed cell culture from an aliquot of cells from Group 2 mixed for scaffold 
loading and grown in a culture plate for 24 hours. B) Fluorescent micrograph showing the presence of GFP-positive 
cells (NOG cells) within the culture shown in A. C) Image of merged A and B images showing that the GFP-
positive NOG cells accounted for a subset of the total population (1:2 NOG:B4). 
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5.4.3 µCT analysis 
Three and 6 weeks after surgery, µCT scans were taken from animals from each treatment group. 
All animals scanned showed healing of the defect with radioopaque tissue that resembled bone. 
There was some overgrowth of the bone around the defect 3 weeks postoperatively (Figure 29) 
that increased in size by 6 weeks (Figure 30). Grossly, there appeared to be less bone in the 
defects treated with 1:2 NOG:B4 cells (Group 2) than in the other treatment groups.  
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 Figure 29: 3D µCT reconstructions showing bone formation 3 weeks postoperatively 
3D reconstructions show the formation of bone in all treatment groups. Qualitative analysis suggested that there was 
less bone formed in Groups 2 and 3 (high doses of Noggin) compared to the other groups. Notice that the Group 5 
reconstruction does not seem to show marked bone overgrowth on the outside of the skull (Group 5, left), but 
overgrowth can be seen intracranially, as shown in the cutaway image (right). 
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 Figure 30: 3D µCT reconstructions showing bone formation 6 weeks postoperatively  
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Analysis of bone volume within the defect (DBV) 3 weeks after surgery (Figure 29) 
showed significant differences among the treatment groups (F=3.88;p<0.05). Groups 2 and 3 
were found to have the smallest defect bone volumes while Groups 1, 4, and 5 seemed to have 
similar amounts of bone formation within the defect (Figure 31). 
 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 31: Defect bone volume (DBV) 3 weeks postoperatively 
Graph depicting the mean volume (±SEM) of bone measured within the defect region. Notice that the groups with 
the highest concentration of Noggin expressing cells (Groups 2 and 3) had the smallest volume of bone within the 
defect.  
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Analysis of mean density of the bone within the defect (DBVMD) 3 weeks 
postoperatively showed significant differences among the treatment groups (F=5.09;p<0.01). 
Group 5 was found to have the least dense bone within the defect among the groups (Figure 32). 
Group 3 (1:5 NOG:B4) had the highest density of bone within the defect 
(549.25±38.2mgHA/cc), though it was only significantly higher than Group 4 and Group 5. 
 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 32: Bone volume mean density within the defect (DBVMD) 3 weeks postoperatively 
Graph showing the mean density of the bone within the defect (±SEM). Group 5 showed significantly lower density 
compared to Groups 1, 2, and 3. 
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There were also significant differences among the groups in the volume of ectopic bone 
(EBV) that was formed outside of the defect. Similar to the volume of bone within the defect 
(DBV), Groups 2 and 3 were found to have the smallest volumes of ectopic bone formed (Figure 
33). Group 5 formed the largest volume of ectopic bone (3.87±0.66mm3), though it was not 
significantly more bone than Groups 1 or 4. 
 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 33: Ectopic bone volume (EBV) 3 weeks postoperatively 
Graph showing the mean volumes of ectopic bone formed by each group (±SEM). Higher amounts of Noggin 
(Groups 2 and 3) led to significantly less ectopic bone formation compared to BMP alone (Group 1) or low 
concentrations of Noggin (Groups 4 and 5). 
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Mean density for ectopic bone volume was significantly different between the treatment 
groups (F=5.74;p<0.01). The ectopic bone formed by Group 2 was significantly more dense 
(503.20±24.8mgHA/cc) than the ectopic bone formed in Groups 1, 4, and 5; but it was not 
significantly more dense than the ectopic bone formed in Group 3 (Figure 34).   
 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 34: Ectopic bone volume mean density (EBVMD) 3 weeks postoperatively 
Graph showing mean density of bone formed outside of the defect (±SEM). The highest concentration of Noggin 
expressing cells tested (Group 2) formed the highest density of ectopic bone. 
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By adding the DBV and EBV together, we calculated an estimated total bone volume 
(TBV) that was compared among the 5 treatment groups. Analysis showed that, again, Groups 2 
and 3, which had the highest concentrations of Noggin (1:2 and 1:3, respectively), had the 
smallest total volume of bone formed compared to Groups 1, 4, and 5 (Figure 35). The bone 
volume within the defect (DBV) and the total bone volume (TBV) were used to achieve an 
efficiency ratio (DBV/TBV). Comparison of the efficiencies of the different treatment groups 
revealed no significant differences among groups (F=2.23;NS). 
 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 35: Total bone volume (DBV+EBV) 3 weeks postoperatively 
Graph showing mean volumes (±SEM) of calculated total bone. Similar to both defect bone volume and ectopic 
bone volume, high concentrations of Noggin (Groups 2 and 3) significantly inhibited total bone formation. 
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Six weeks after surgery (Figure 30), the comparison among the treatment groups was 
much different than it was 3 weeks postoperatively. The volume of bone within the defect (DBV) 
was compared among groups and no significant differences were found (F=1.70;NS). All of the 
groups had volumes that ranged between 2.3 and 4.6 mm3. Analysis of the mean density of the 
DBV, however, showed significant differences between the groups (F=10.34;p<0.01). In general, 
the highest ratios of Noggin to BMP (1:2 and 1:3) led to the formation of denser bone. The bone 
formed within the defect showed significantly higher density in Group 2 compared to all other 
groups (Figure 36). 
 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 36: Mean density of the bone formed within the defect 6 weeks postoperatively 
Graph showing mean density of the defect bone volume (±SEM). Group 2 showed significantly higher bone density 
within the defect compared to all other groups. 
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Analysis of the ectopic bone volume 6 weeks postoperatively showed no significant 
differences among groups (F=2.14;NS), though Group 2 showed the smallest volume of ectopic 
bone (1.09±0.9mm3) compared to the other groups. Ectopic bone volume mean density was 
significantly different among the treatment groups 6 weeks postoperatively (F=8.77;p<0.01). The 
ectopic bone that was formed in animals in Group 2 had significantly higher density compared to 
the density of the ectopic bone formed in all other treatment groups (Figure 37). There were no 
other differences in ectopic bone mean density between any of the treatment groups. 
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 37: Mean density of ectopic bone 6 weeks postoperatively 
Graph showing mean density (±SEM) of bone formed outside of the defect region. Group 2 formed significantly 
higher density ectopic bone compared to other groups. 
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There were no significant differences in the total bone volume among treatment groups 6 
weeks postoperatively (F=2.11;NS). Mean total bone volumes ranged from 3.4mm3 (Group 2) to 
15.3mm3 (Group 5). Group 5 showed the largest amount of total bone formation, partially due to 
a single animal that showed significant bone overgrowth (Figure 38).  
 
 
Figure 38: 3D µCT reconstruction of one animal from Group 5 that showed significant bone overgrowth 
Image depicting the overgrowth of bone that can occur after ex vivo BMP4 gene therapy. High concentrations of 
Noggin expressing cells mixed with the BMP4 expressing cells inhibited this type of bone overgrowth in this study. 
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Comparison of the efficiencies of each treatment showed significant differences 
(F=5.54;p<0.01) among the treatment groups. Group 2 showed the highest mean efficiency. 
Approximately 71% of the bone that had formed 6 weeks postoperatively was located within the 
defect. This efficiency was significantly better than all other groups (Figure 39).  
 
 
Group 1 
1:2 control:BMP4 
Group 2 
1:2 NOG:BMP4 
Group 3 
1:5 NOG:BMP4 
Group 4 
1:10 NOG:BMP4 
Group 5 
1:20 NOG:BMP4 
Figure 39: Efficiency ratings (DBV/TBV) 6 weeks postoperatively 
Graph showing mean efficiency for each group (±SEM). Group 2 (1:2 NOG:B4) was the most efficient treatment, 
with approximately 71% of the total bone was formed within the defect. 
 
The relationship between bone volume and bone density was assessed at each 
postoperative time point by comparing the measured defect bone volume (DBV) to the defect 
bone volume mean density (DBVMD) and by comparing the measured ectopic bone volume 
(EBV) to the ectopic bone volume mean density (EBVMD). Among the groups tested, we found 
that, at both 3 and 6 weeks postoperatively, there were negative correlation coefficients (r=-0.58 
and r=-0.32, respectively) between DBV and DBVMD. This correlation was significant (p<0.01) 
only at the 3 week time point (Figure 40A). Similar results were found for the ectopic bone 
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analysis. There was a negative correlation coefficient between EBV and EBVMD at both 3 and 6 
weeks postoperatively (r=-0.64 and r=-0.19, respectively) with the correlation being significant 
(p<0.01) 3 weeks postoperatively (Figure 40B). 
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Figure 40: Scatterplot graphs showing correlations between bone volume and bone density 
A) Graph showing a negative correlation between DBV and DBVMD for all animals 3 weeks postoperatively (r=-
0.578,p<0.01). B) Graph showing a negative correlation between EBV and EBVMD of all animals 3 weeks 
postoperatively (r=-0.640,p<0.01). 
 
 The relationship between total bone volume and either defect bone volume or ectopic 
bone volume was also tested for all animals at both time points postoperatively. We found that 
there were significant positive correlations between total bone volume and defect bone volume 
(r=0.860;p<0.001) and between total bone volume and ectopic bone volume (r=0.983;p<0.001). 
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5.5 DISCUSSION 
In all bone regeneration applications, it is important to control the amount of bone that forms 
following a particular therapy. The necessity for control is most acute in craniofacial 
reconstruction because of the proximity of bone to vital structures such as blood vessels, nerves, 
and sensory organs. 
We have previously shown that bone healing can be improved through the use of ex vivo 
gene therapy techniques based on muscle-derived cells expressing BMPs [197, 199, 256, 258]. In 
an attempt to both elucidate the interaction between vascular endothelial growth factor (VEGF) 
and BMP and to improve bone healing, combinatorial therapies were developed [256, 269]. 
These studies were among the first to utilize gene-based approaches to test therapies using 
combinations of different growth factors. 
Peng, et al. reported on the development of an inducible retroviral vector encoding BMP4 
expression in 2004 [253]. This vector was developed in part to enable the temporal control of 
bone formation. When this vector was used to heal calvarial defects in an ex vivo gene-based 
therapy, it was observed that there was bone formation even without the induction of BMP4 
expression and that this “background” bone formation could be inhibited by adding cells that 
expressed Noggin, a known BMP antagonist [245]. That study also showed that less ectopic bone 
was formed after BMP expression was induced in the presence of Noggin expressing cells 
compared to when BMP was expressed in the absence of Noggin expressing cells [245].  
Noggin expression has been colocalized with BMP expression during normal bone 
healing [210]. BMP stimulation has also been shown to increase Noggin expression in 
osteogenic tissues [129, 270]. Therefore, we believed that the concurrent expression of BMP4 
and its antagonist, Noggin, may influence the amount and quality of bone that forms after BMP-
 110 
based therapies. The current experiment was designed to test whether the amount and quality of 
bone could be regulated through biologic means. 
The results of this study show a dose response to Noggin. The defects treated with higher 
ratios of Noggin cells (1:2 and 1:5, Groups 2 and 3, respectively) formed less bone than defects 
treated with BMP expressing cells only (Group 1) or low ratios of Noggin expressing cells (1:10 
and 1:20, Groups 4 and 5, respectively). This trend was observed for the volume of bone within 
the defect, ectopic bone volume, and total bone volume. These data support the intuitive 
hypothesis that increased amount of antagonist (Noggin) will cause increased inhibition of 
agonist (BMP4). 
The data also suggest that the therapies that induced less bone produced the bone with the 
highest density. Both 3 and 6 weeks postoperatively, the groups with smaller bone volumes (both 
DBV and EBV) demonstrated more dense bone. In fact, 3 weeks postoperatively, there were 
significant negative correlations between the volume of bone and the density of the bone. This 
data suggest that more is not necessarily better. Although a vast majority of the research 
surrounding bone regeneration is interested in creating the most bone in the shortest amount of 
time, the results from such research may be misleading. For this reason, we believe that the 
analytical techniques employed in the current study will lead to more accurate interpretation of 
the effectiveness of bone regeneration techniques. 
It is interesting to note that 3 weeks after surgery, Group 2 (1:2 Nog:B4 cells) had 
significantly denser bone within the defect compared to Group 1 (B4 cells only), but the volume 
of the bone within the defect was not significantly different. These results are promising in that it 
was possible to create bone of higher density without significantly decreasing the total volume of 
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bone that was formed. These data also suggest another means by which Noggin improves BMP 
induced bone formation, in addition to simply decreasing the volume of bone that formed. 
One possible means of improving the density of the bone that forms is through the 
inhibition of bone resorption. Bone is normally degraded by osteoclasts during remodeling. BMP 
signaling has been suggested as a positive regulator of bone resorption and in osteoclastic 
differentiation [271, 272]. It has also been suggested that, because BMPs are notoriously 
inductive of bone formation, BMPs may act as inhibitors of osteoclastic activity [273]. Because 
there is still debate regarding the role of BMPs in osteoclastic differentiation and activity, it is 
difficult to determine whether the increases in bone density observed in the groups with the 
highest ratios of Noggin expressing cells is caused by the inhibition of osteoclasts. 
Overall, extreme caution should be used in the interpretation of the data presented here. It 
must be noted that the results presented above do not agree with previously published data. Our 
previous studies showed the presence of a large mass of disorganized trabecular bone much 
larger than the defect only 3 weeks after surgery [245]. The current study found only minimal 
bone formation up to 6 weeks postoperatively. We may be able to attribute this difference in the 
effectiveness of our bone induction to the formation of tumors. 
All animals in this study formed large tumors under their skin in the region of the 
implanted cells. These tumors were not evident during the µCT scanning 3 weeks 
postoperatively. By 6 weeks after surgery, the tumors were larger than the cranial vault and the 
animals were killed immediately. The 6 week µCT scans were performed on fixed skulls from 
these animals.  
The cause of the tumors is not understood. The cell population that was used had recently 
been used by another investigator in our laboratory for a similar ex vivo bone induction study, 
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with no evidence of tumor formation. It seems logical that the formation of tumors within the 
implanted tissue would adversely affect the formation of bone, resulting in the differences 
observed between this study and previous studies by our group. 
Regardless of the formation of tumors by 6 weeks postoperatively, we believe that this 
study supports our hypothesis that the simultaneous implantation of Noggin expressing cells with 
BMP4 expressing cells can assist in minimizing ectopic bone formation and improve the quality 
of the bone that forms within the defect. Future studies will involve the use of different cell lines, 
a focus on Noggin:BMP ratios between 1:1 and 1:5, and the biomechanical testing of the 
regenerated bone as another measure of the quality of the bone that forms. 
This study is the first to attempt to control the amount and quality of bone that is 
regenerated using BMP-based therapies using a biologically-based strategy. The results, though 
confounded by the formation of tumors, suggest that combined Noggin and BMP therapies 
warrant further investigation. 
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6.0 CONCLUSIONS 
Many advances have been made in our understanding of bone growth, remodeling, and 
regeneration. The current task to be undertaken is the translation of this body of knowledge to 
clinical application. Toward that end, an understanding of molecular biology, cell biology, and 
gene therapy can be used to advance the field of bone regeneration. 
The primary focus of the work presented here was an exploration into biologically-based 
strategies to control bone formation. The use of currently available strategies to advance bone 
formation may also be utilized to inhibit bone formation and to improve the quality of therapy in 
cases of hyperostosis. A series of three studies were designed to assess the ability of Noggin, an 
extracellular inhibitor of BMPs, to regulate and control bony wound healing in a variety of 
circumstantes. In the first study, Noggin protein, inhibited bone formation in a rabbit model of 
human nonsyndromic craniosynostosis. This work also showed that a single application of 
Noggin protein within a collagen vehicle could inhibit postoperative resynostosis and improve 
overall craniofacial growth. The second study developed a novel mouse model of postoperative 
resynostosis to test strategies to control calvarial bone healing. This model was then used to 
assess the ability of Noggin ex vivo gene therapy to inhibit bone formation within small calvarial 
defects in mice. In the third study, it was found that a therapy which combined the application of 
both BMP4 and its antagonist, Noggin, minimized the formation of ectopic bone and improved 
the quality of bone that forms within the defect. 
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There were some interesting results that need to be considered. In the second chapter, an 
initial increase in the defect size was observed in the Noggin treated rabbits. As was discussed, it 
was hypothesized that this increase was due to the expansion of the calvaria after release of the 
synostosed suture. It was also speculated that this same expansion occurred in the control groups; 
but, because healing was occurring as well, no expansion was observed. There could be another 
reason for the expansion of the Noggin treated defects. The Noggin treatment may have, 
somehow, recruited more osteoclasts to the defect site and induced resorption of the bone in the 
defect area. The interaction between BMP signaling and osteoclastogenesis is still being debated, 
so it is difficult to know whether the inhibition of BMP signaling through Noggin treatment 
induced bone resorption.  
The cause for the inhibition of defect healing by GFP expressing MDSCs is also 
debatable. In that study, the GFP treated defects were significantly larger than untreated defects 
both 4 and 8 weeks after surgery, according to the µCT data. It was speculated in the conclusions 
of Chapter 4 that this inhibition may have been caused by an immune reaction by the normal 
mice to either the gelatin sponge vehicle or to the MDSCs themselves. Another possible 
explanation would be that the MDSCs express endogenous inhibitors of bone formation. 
However, there is a far from a complete understanding of the effects that stem cells have on their 
environment and the explanation is still speculative. It could also be possible that these cells 
express many different growth factors that, in this case, inhibited bone formation. Stem cells 
have also been shown to chemoattract other cell types. By attracting and promoting osteoclastic 
activity, the MDSCs could have induced bone resorption in the defect area. The field of tissue 
engineering must constantly be aware that the cellular component is never inert. Though the 
 115 
intent was to introduce cells that would produce Noggin or GFP in this study, there is no way for 
us to control the multitude of interactions of which the stem cells are involved. 
Another observation that may have broader implications for the field of bone tissue 
engineering is that a single-dose Noggin treatment had lasting effects on bone healing. Also, in 
the fourth chapter, the longer-term, ex vivo gene therapy only seemed to affect healing in the 
first few weeks after surgery. In this same study, it was observed that untreated control defects 
healed rapidly within the first 4 weeks after surgery. Together, these results suggest that there is 
a critical time, soon after the defect is created, where treatment may have its effect. Therefore, it 
may be possible to delay bone healing early in the healing process, resulting in altered bone 
growth in the longer term. This possibility changes the perceived need for sustained delivery of 
the therapeutic protein. Through rigorous testing of the long-term results of short-term therapies, 
we should be able to better understand the bone healing process, leading to the development of 
more effective biologically-based adjuncts to conventional surgery. 
Lastly, by elucidating the interaction between BMP4 and its inhibitor, Noggin, in the fifth 
chapter, it became apparent that dosage is extremely important. It was hypothesized that the 
addition of Noggin expressing cells to the BMP4 treatment minimized the formation of ectopic 
bone and increased the density of the bone that formed within the defect because there was an 
appropriate dose of BMP4 supplied to the defect site. This data should prove to have broader 
implications in bone tissue engineering by pointing out that therapies should be developed to 
improve specific outcomes. These findings suggest that therapies directed toward the most rapid 
creation of the largest volume of new bone should be avoided. This study has shown that more is 
not necessarily better by demonstrating that there is a negative correlation between bone volume 
and bone density. Also, the techniques used to analyze bone formation in this study changed the 
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way we understand treatment efficiency. Standard radiographic and histological analyses are 
more useful in the determination of the presence of bone tissue, rather than the quality of the 
bone tissue. By using new technology, this study was able to directly compare the density of the 
bone that formed within a defined area, the defect region. Similar analytical techniques should 
improve our ability to evaluate and compare strategies to improve bone healing.   
6.1 FUTURE DIRECTIONS 
The use of Noggin to control bone formation warrants further investigation. It is believed that the 
use of a naturally occurring antagonist, such as Noggin, can be readily turned into a clinical 
reality, especially in cases of single suture, nonsyndromic craniosynostosis. Technologies are 
being developed for drug delivery to assist in the delivery of Noggin protein for longer durations. 
Also, there is an acute need for strategies to control the size and shape of the bone that forms 
following regenerative therapies. To this end, it is important to continue to develop and test both 
physical (through scaffold manipulation) and biological (through combinatorial therapies) means 
to control bone formation.  
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